A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura
Phase: PHASE3
Conditions: Migraine, With or Without Aura
Sponsor: Allergan

NCT02873221 
 
 
Study ID: UBR‐MD‐04 
 
 
 
Title: A Multicenter, Randomized, Open‐Label Extension Study to Evaluate the Long‐Term Safety and 
Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura 
 
 
Protocol Amd 3 Date: 11‐Apr‐2018 
 
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
1
GDD-TA-T-004 v2015.10
Title Page
ALLERGAN – CONFIDENTIAL
The following contains confidential, proprietary information which is the property of 
Allergan
A MULTICENTER, RANDOMIZED, OPEN-LABEL EXTENSION STUDY TO 
EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL 
UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT 
AURA
Protocol Number:  
UBR-MD-04 Amendment 3
Phase:
3
Name of Investigational Product:
Ubrogepant
Sponsor:
Allergan Pharmaceuticals 
Authorized US Agent
International Limited
Allergan Sales, LLC
Clonshaugh Industrial Estate
2525 Dupont Drive
Coolock
Irvine, California USA  92612
Dublin 17
+1-714-246-4500
Ireland
+1-800-347-4500
Emergency Telephone Number(s):
Refer to the Study Contacts Page
Serious Adverse Event Reporting 
Fax Number:
Allergan Medical Safety Physician 
Contact Information:
Please see Study Contact Sheet
Allergan Signatory:
Original Protocol Date:
02 May 2016
Protocol Amendment 1 Date: 
15 Nov 2016
Protocol Amendment 2 Date: 
06 Dec 2017
Protocol Amendment 3 Date:
11 Apr 2018
The following information can be found on FDA Form 1572 and/or study contacts page:  
Name and contact information of Allergan study personnel and Emergency Telephone 
Numbers; name, address, and statement of qualifications of each investigator; name of each 
subinvestigator working under the supervision of the investigator; name and address of the 
research facilities to be used; name and address of each reviewing IRB; US 21 CFR 312.23 
section 6(iii)b.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
2
GDD-TA-T-004 v2015.10
INVESTIGATOR SIGNATURE PAGE
INVESTIGATOR:
I agree to:

Implement and conduct this study diligently and in strict compliance with the 
protocol, good clinical practices and all applicable laws and regulations.

Maintain all information supplied by Allergan in confidence and, when this 
information is submitted to an Institutional Review Board (IRB), Independent Ethics 
Committee (IEC) or another group, it will be submitted with a designation that the 
material is confidential.

Ensure that all persons assisting with the trial are adequately informed about the 
protocol, the investigational product(s), and their trial-related duties and functions.
I have read this protocol in its entirety and I agree to all aspects.
Investigator Printed Name
Signature
Date

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
3
GDD-TA-T-004 v2015.10
Table of Contents
Title Page .................................................................................................................................. 1
Table of Contents...................................................................................................................... 3
List of Tables ............................................................................................................................ 6
Protocol Summary .................................................................................................................... 8
1.
Background and Clinical Rationale................................................................................. 13
2.
Study Objectives and Clinical Hypotheses...................................................................... 15
2.1
Study Objectives .................................................................................................... 15
2.2
Clinical Hypothesis................................................................................................ 15
3.
Study Design.................................................................................................................... 15
3.1
Adjudication Committee and Data Safety Monitoring Board................................ 16
4.
Study Population and Entry Criteria................................................................................ 16
4.1
Number of Patients................................................................................................. 16
4.2
Study Population Characteristics ........................................................................... 16
4.3
Inclusion Criteria.................................................................................................... 17
4.4
Exclusion Criteria................................................................................................... 17
4.5
Permissible and Prohibited Medications/Treatments............................................. 18
4.5.1
Permissible Medications/Treatments ...................................................... 18
4.5.1.1
Acute Treatment/Rescue Medication................................ 19
4.5.1.2
Definition of Females of Childbearing Potential and/or 
Acceptable Contraceptive Methods .................................. 20
4.5.2
Prohibited Medications/Treatments ........................................................ 20
4.5.3
Special Diet or Activities ........................................................................ 21
5.
Study Treatments............................................................................................................. 21
5.1
Study Treatments and Formulations ...................................................................... 21
5.2
Control Treatment.................................................................................................. 21
5.3
Methods for Masking/Blinding.............................................................................. 21
5.4
Treatment Allocation Ratio and Stratification....................................................... 22
5.5
Method for Assignment to Treatment Groups/Randomization.............................. 22
5.6
Treatment Regimen and Dosing............................................................................. 23
5.6.1
Ubrogepant .............................................................................................. 23
5.6.2
Usual Care ............................................................................................... 23

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
4
GDD-TA-T-004 v2015.10
5.6.3
Optional Second Dose and Rescue Medication ...................................... 24
5.7
Storage of Investigational Products/Treatments .................................................... 24
6.
Response Measures and Summary of Data Collection Methods..................................... 24
6
6.2
Safety Measures ..................................................................................................... 26
6.2.1
Adverse Events........................................................................................ 26
6.2.2
Events of Clinical Interest ....................................................................... 27
6.2.3
Clinical Laboratory Determinations........................................................ 27
6.2.4
Vital Sign Measurements ........................................................................ 28
6.2.5
Physical Examinations ............................................................................ 28
6.2.6
Electrocardiograms.................................................................................. 28
6.2.7
Suicidality Assessment............................................................................ 29
6.2.8
Cardiovascular Disease Risk................................................................... 29
6.3
Other Study Supplies ............................................................................................. 30
6.4
Summary of Methods of Data Collection .............................................................. 30
7.
Statistical Procedures....................................................................................................... 30
7.1
Analysis Populations.............................................................................................. 30
7.1.1
Modified Intent-to-Treat Population ....................................................... 30
7.1.2
Safety Population .................................................................................... 31
7.2
Collection and Derivation of Efficacy Assessments.............................................. 31
7.3
Hypothesis and Methods of Analysis..................................................................... 32
7.3.2
Safety Analyses ....................................................................................... 33
7.3.2.1
Adverse Events.................................................................. 34
7.3.2.2
Cardiovascular Risk .......................................................... 35
7.3.2.3
Clinical Laboratory Parameters......................................... 35
7.3.2.4
Vital Sign Measurements.................................................. 36
7.3.2.5
Electrocardiogram............................................................. 37
7.3.2.6
Suicidality Assessment...................................................... 37
7.3.2.7
Potential Hy’s Law............................................................ 37
7.4
Subgroup Analyses ................................................................................................ 38
7.6
Interim Analyses .................................................................................................... 38
8.
Study Visit Schedule and Procedures.............................................................................. 39

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
5
GDD-TA-T-004 v2015.10
8.1
Patient Entry Procedures........................................................................................ 39
8.1.1
Overview of Entry Procedures ................................................................ 39
8.1.2
Informed Consent and Patient Privacy.................................................... 39
8.5
Instructions for the Patients.................................................................................... 44
8.6
Unscheduled Visits ................................................................................................ 44
8.7
Compliance with Protocol...................................................................................... 44
8.8
Early Discontinuation of Patients .......................................................................... 45
8.9
Withdrawal Criteria................................................................................................ 45
8.10 Study Termination.................................................................................................. 46
9.
Adverse Events ................................................................................................................ 46
9.1
Definitions.............................................................................................................. 46
9.1.1
Adverse Event ......................................................................................... 46
9.1.2
Serious Adverse Event ............................................................................ 47
9.1.3
Severity.................................................................................................... 47
9.1.4
Relationship to Study Drug or Study Procedure ..................................... 48
9.2
Procedures for Reporting Adverse Events............................................................. 48
9.3
Procedures for Reporting a Serious Adverse Event............................................... 48
9.4
Exposure to Investigational Product During Pregnancy........................................ 49
9.5
ALT or AST Elevations ......................................................................................... 49
9.6
Potential Hy’s Law Cases ...................................................................................... 51
9.7
Procedures for Unmasking of Investigational Product .......................................... 51
10. Administrative Items ....................................................................................................... 52
10.1 Protection of Human Patients................................................................................. 52
10.1.1
Compliance with Informed Consent Regulations (US 21 CFR Part 50) 
and Relevant Country Regulations.......................................................... 52
10.1.2
Compliance with IRB or IEC Regulations.............................................. 52
10.1.3
Compliance with Good Clinical Practice ................................................ 52

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
6
GDD-TA-T-004 v2015.10
10.1.4
Compliance with Electronic Records; Electronic Signatures.................. 52
10.1.4.1
Regulations (US 21CFR Part 11)...................................... 52
10.2 Changes to the Protocol ......................................................................................... 53
10.3 Patient Confidentiality ........................................................................................... 53
10.3.1
Patient Privacy......................................................................................... 53
10.4 Documentation....................................................................................................... 53
10.4.1
Source Documents................................................................................... 53
10.4.2
Case Report Form Completion................................................................ 54
10.4.3
Study Summary....................................................................................... 55
10.4.4
Retention of Documentation ................................................................... 55
10.5 Labeling, Packaging, and Return or Disposal of Investigational 
Products/Treatments............................................................................................... 55
10.5.1
Labeling/Packaging................................................................................. 55
10.5.2
Clinical Supply Inventory ....................................................................... 56
10.5.3
Return or Disposal of Investigational Products/Treatments and/or 
Supplies ................................................................................................... 56
10.6 Monitoring by Allergan.......................................................................................... 56
10.7 Handling of Biological Specimens/Samples.......................................................... 56
10.8 Publications............................................................................................................ 57
10.9 Coordinating Investigator....................................................................................... 57
11. References........................................................................................................................ 57
12. Attachments..................................................................................................................... 59
12.1 Examination Procedures, Tests, Equipment, and Techniques ............................... 59
12.1.1
International Classification of Headache Disorders, 3rd Edition, Beta 
Version .................................................................................................... 59
12.2 Examples of Prohibited Medications ..................................................................... 75
12.3 Glossary of Abbreviations ..................................................................................... 78
12.4 Protocol Amendment 1 Summary.......................................................................... 81
12.5 Protocol Amendment 2 Summary.......................................................................... 88
12.6 Protocol Amendment 3 Summary.......................................................................... 92
List of Tables

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
7
GDD-TA-T-004 v2015.10
Table 2
Treatments Administered for Initial and Optional Second Dose.................... 23
Table 3
Clinical Laboratory Parameters ...................................................................... 28

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
8
GDD-TA-T-004 v2015.10
Protocol Summary
Study Compound:  Ubrogepant
Phase: 3
Study Objective:  To evaluate the safety and tolerability of intermittent treatment with ubrogepant for the 
acute treatment of migraine over 1 year
Clinical Hypotheses:  Ubrogepant 50 and 100 mg is safe and tolerable for the acute treatment of migraine 
over 1 year
Study Design
Structure: multicenter, randomized, open-label, 52-week extension study
Duration: 52 weeks
Study Treatment Groups: usual care, ubrogepant 50 mg, or ubrogepant 100 mg
Controls:  Not applicable
Dosage/Dose Regimen: Patients randomized to either of the ubrogepant arms will treat up to 8 migraine 
attacks (of any pain severity) per every 4-week period at home for a total of 1 year. Patients have the option 
to take a second dose of ubrogepant if the patient has either a nonresponding migraine or a migraine 
recurrence. The second dose of ubrogepant will be identical to the first dose.
Patients randomized to the usual-care arm will be instructed to treat their migraine with medications that 
they routinely use to relieve a migraine attack.
 
 
 
 
Study Population Characteristics
Number of Patients:  Approximately 1200 patients will be randomized (400 patients per arm) from 
approximately 200 centers in the United States
Condition/Disease:  Migraine with or without aura
Key Inclusion Criteria:  To be eligible for study participation, patients must have completed 1 of the lead-in 
studies, UBR-MD-01 or UBR-MD-02, 
 
 
Key Exclusion Criteria:  Patients with clinically significant electrocardiogram (ECG), vital sign, physical 
examination, or laboratory abnormalities, or who require prohibited concomitant medications (see 
Section 4.5.2)
Response Measures
 
 
Safety:  AEs, physical examinations, clinical laboratory determinations, vital sign measurements, ECG
parameters, and the Columbia –Suicide Severity Rating Scale (C-SSRS)

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
9
GDD-TA-T-004 v2015.10
General Statistical Methods and Types of Analyses:  
 
 
 
 
 
 
The safety analyses will be performed using the Safety population and will include AEs, clinical laboratory 
evaluations, vital sign measurements, ECG parameters, and the C-SSRS. For each of the clinical, laboratory, 
vital sign, and ECG parameters, the last nonmissing safety assessment before the first dose in the lead-in 
study will be used as the baseline for all analyses of that safety parameter. Continuous variables will be 
summarized by the number of patients and mean, SD, median, minimum, and maximum values. Categorical 
variables will be summarized by number and percentage of patients.
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
10
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
11
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
12
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
13
GDD-TA-T-004 v2015.10
1.
Background and Clinical Rationale
What is Migraine and How Prevalent is It?
Migraine affects 18% of women and 6% of men in the United States with a peak prevalence 
occurring between the ages of 25 to 55 years. Approximately one-third of migraineurs have 
3 or more migraine headaches per month, and over half report severe impairment or the need 
for bed rest during an attack (Lipton 2007). In the United States, work loss due to migraine is 
estimated to cost ~$13 billion annually (Hu 1999). Prevalence is similar in Europe, with 
migraine headache affecting 17.6% of women and 8% of men (Stovner 2010). It is currently 
ranked by the World Health Organization as 19th among causes of disability (Katsarava 
2012). 
Migraine is typically characterized by attacks of throbbing, unilateral headache of moderate 
or severe pain intensity, associated with nausea, vomiting, and/or sensitivity to light 
(photophobia) and sound (phonophobia). In about 25% of individuals, migraine headache 
may be preceded by focal neurological dysfunction (aura). Improving the diagnosis and 
optimizing treatments for migraine have been recognized as critically important to reduce the 
global burden of migraine (Katsarava 2012).
Because there are no biological markers for migraine, diagnosis is based on clinical history, 
examination, and the exclusion of other headache disorders. Physicians apply clinical criteria 
to guide diagnoses and subsequent treatment. Episodic migraine is a syndrome diagnosis 
applied to patients with migraine (with or without aura) who have 1 to 14 headache days per 
month. Chronic migraine is a specific International Classification of Headache Disorders 
criteria, 3rd edition beta version (ICHD-3 beta) diagnosis applied to a subset of patients with 
≥ 15 headache days per month (ICHD-3 beta 2013; Katsarava 2012; Olesen 2006). 
What is CGRP and Its Relationship to Migraine?
Calcitonin gene-related peptide (CGRP) is a neuropeptide implicated in the pathophysiology 
of migraine. CGRP levels in the cranial venous outflow (ie, external jugular vein) are 
increased during a migraine attack (Goadsby 1993) and exogenously administered CGRP has 
been shown to trigger migraine-like headache in migraineurs. The majority (80 to 90%) of 
trigeminal Aδ fibers that innervate the dura contain CGRP, suggesting that these fibers may 
be involved in sterile neurogenic inflammation and migraine pain transmission. Furthermore, 
the CGRP receptor is present on human meningeal and cerebral blood vessels. These 
observations suggest that activation of the trigeminovascular system, with release of CGRP, 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
14
GDD-TA-T-004 v2015.10
may play a key role in migraine pathogenesis and that inhibition of CGRP function may yield 
a novel therapeutic approach to treating migraine.
Establishment of CGRP Antagonism to Treat Migraine
The ability of CGRP antagonism to relieve pain in the acute treatment of migraine was 
established by using an intravenous (IV) formulation of olcegepant (Olesen 2004), and 
replicated by Merck & Co., Inc., with an oral formulation of telcagepant, a highly selective 
CGRP receptor antagonist (CGRP RA). In Phase 3 studies, telcagepant was superior to 
placebo in the primary endpoints of 2-hour pain freedom, 2-hour pain relief, and the absence 
of associated symptoms (photophobia, phonophobia, and nausea), as well as the key 
secondary endpoint of 24-hour sustained pain freedom (SPF) (Connor 2009). Serum alanine 
aminotransferase (ALT) increases were observed with telcagepant, as well as with a second 
CGRP antagonist, MK-3207. For this reason, the development of these compounds was 
stopped. 
What is Ubrogepant?
Ubrogepant, a novel CGRP receptor antagonist that is chemically distinct from both 
telcagepant and MK-3207, is now being developed for the acute treatment of migraine. 
Preclinical and clinical studies conducted to date for ubrogepant have shown no evidence of 
hepatotoxicity.
A Phase 2b clinical study was conducted, which compared 1, 10, 25, 50, and 100 mg doses of 
ubrogepant to placebo in the acute treatment of migraine. Overall, all the ubrogepant doses 
tested were well tolerated and the adverse event (AE) profile of all ubrogepant doses did not 
differ significantly from placebo. For the primary efficacy endpoint of pain freedom at 
2 hours, ubrogepant doses of 1 and 10 mg did not differ from placebo, but doses of 25, 50, 
and 100 mg were better than placebo. For the primary efficacy endpoint of pain relief at 
2 hours none of the ubrogepant doses differed from placebo, probably due to a high placebo 
response rate.
The absence of migraine-associated symptoms of photophobia, phonophobia, and nausea 
were assessed as key secondary endpoints. Ubrogepant doses of 50 and 100 mg were 
significantly better than placebo for absence of phonophobia and photophobia at 2 hours, 
whereas 25 mg did not differ from placebo. None of the ubrogepant doses differed from 
placebo for the endpoint of absence of nausea at 2 hours. Measures of sustained migraine 
headache relief (2 to 24 hours and 2 to 48 hours SPF and sustained pain relief) generally 
suggested that ubrogepant 50 mg and 100 mg were more effective than the 25 mg dose.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
15
GDD-TA-T-004 v2015.10
This trial is being conducted to evaluate the long-term safety and tolerability of ubrogepant 
for the acute treatment of migraine.
The purpose of including the usual-care arm will be to contextualize any safety findings that 
may occur over the course of a year in the ubrogepant arms. In open-label designs without a 
comparator arm, it can be difficult to interpret any safety findings that may arise in the 
experimental treatment arm. The proposed inclusion of the usual-care arm in this study is 
intended to address this limitation. Because of the stated purpose of the usual-care arm, 
efficacy data will not be collected from patients randomized to this arm.
2.
Study Objectives and Clinical Hypotheses
2.1
Study Objectives
To evaluate the safety and tolerability of intermittent treatment with ubrogepant for the acute 
treatment of migraine over 1 year.
2.2
Clinical Hypothesis
Ubrogepant 50 and 100 mg is safe and tolerable for the acute treatment of migraine over 
1 year.
3.
Study Design
This multicenter, randomized, open-label, 52-week extension study will enroll approximately 
1200 patients from approximately 200 centers in the United States. Patients will be 
randomized (1:1:1) to 1 of the following 3 treatment groups: usual care, ubrogepant 50 mg, 
or ubrogepant 100 mg (400 patients per arm). The study is open-label; however, 
randomization to the ubrogepant arms (50 and 100 mg) will be blinded. If and when an 
interim analysis occurs, the doses will be unblinded (see Section 7.6).
Patients randomized to either of the ubrogepant arms will treat up to 8 migraine attacks (of 
any pain severity) per 4-week period at home for a total of 1 year. Patients have the option to 
take a second dose of ubrogepant or rescue medication if the patient has either a 
nonresponding migraine or a migraine recurrence. The second dose of ubrogepant will be 
identical to the first dose. For detailed information on migraine treatment regimens, including 
optional second dose and rescue medication, see Section 5.6.
Patients randomized to the usual-care arm will be instructed to treat their migraine with 
medication(s) that they routinely use to relieve a migraine attack. Their usual medication(s) 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
16
GDD-TA-T-004 v2015.10
for acute treatment will be identified at Visit 1 and any changes throughout the study will be 
recorded in the electronic case report form (eCRF).
 
 
 
 
. 
The primary outcome is safety and tolerability. The planned safety assessments include 
collection of AEs, clinical laboratory determinations, ECGs, vital sign measurements, 
physical examinations, and the Columbia-Suicide Severity Rating Scale (C-SSRS). 
3.1
Adjudication Committee and Data Safety Monitoring Board
The Adjudication Charter will be established and will describe the process for the 
surveillance, monitoring, and adjudication by the Clinical Adjudication Committee of events 
of post-treatment elevations of ALT and/or aspartate aminotransferase (AST) ≥ 3 times the 
upper limit of normal (ULN) in the ubrogepant program. The purpose of this committee 
charter will be to provide a standardized process for the adjudication of data associated with 
these events in order to determine whether the elevation was due to ubrogepant or not, and to 
determine whether there was a confounding factor. 
An independent Data Safety Monitoring Board will also be established to review safety data 
and summary reports, identify any safety issues and trends, and make recommendations to 
the Allergan, including modification or early termination of a trial, if emerging data show 
unexpected and clinically significant adverse effects of treatment. 
4.
Study Population and Entry Criteria
4.1
Number of Patients 
Approximately 1200 patients will be randomized (400 patients per arm) from approximately 
200 centers in the United States.
4.2
Study Population Characteristics
This study will include adult patients with migraine with or without aura who completed 
Study UBR-MD-01 or UBR-MD-02.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
17
GDD-TA-T-004 v2015.10
4.3
Inclusion Criteria
To be eligible to participate in the study, patients must meet the following criteria:
1. Written informed consent and patient privacy information (eg, Written Authorization 
for Use and Release of Health and Research Study Information) obtained from the 
patient prior to initiation of any study-specific procedures.
2. Completed Study UBR-MD-01 or Study UBR-MD-02.
 
 
 
4.4
Exclusion Criteria
Patients who meet any of the following criteria will not be eligible to participate in the study:
 
2. Requirement for any medication during the study that is on the list of prohibited 
concomitant medications (see Sections 4.5.2 and 12.2) that cannot be discontinued or 
switched to an allowable alternative medication.
 
 
 
 
 
 
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
18
GDD-TA-T-004 v2015.10
 
 
 
 
 
 
 
 
4.5
Permissible and Prohibited Medications/Treatments
4.5.1
Permissible Medications/Treatments
Medications that are not specifically prohibited are allowed, with the following clarifications 
and restrictions for patients taking ubrogepant. Note that for patients assigned to the 
usual-care arm, these restrictions do not apply.
The following medications are allowed during the study but are prohibited within 48 hours 
prior to taking ubrogepant:

any triptan

any ergot derivative

any opioid

any nonsteroidal anti-inflammatory drug (NSAID)

any other form of analgesic (including acetaminophen)

any antiemetic agent

any proton pump inhibitor

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
19
GDD-TA-T-004 v2015.10
The following medications are allowed during the study, but are prohibited within 24 hours 
prior to taking investigational product (IP):

any antacid

any H2 blocker
Examples of allowed but restricted medications listed above are displayed in Section 12.2.

Aspirin up to 325 mg/day is allowed for cardiac prophylaxis.

Daily use of pregabalin is allowed. 
Patients on a stable prescribed dose of selective serotonin reuptake inhibitors (SSRI) or 
serotonin norepinephrine reuptake inhibitors (SNRI) in the lead-in study should continue 
without change in dose throughout this study.
Patients on migraine prophylactic medication (eg, beta-blocker, tricyclic antidepressant, 
topiramate, valproic acid, botulinum toxin) in the lead-in study should continue without 
change in dose throughout this study.
Therapy considered necessary for the patient's welfare may be given at the discretion of the 
investigator. If the permissibility of a specific medication/treatment is in question, please 
contact Allergan.
4.5.1.1
Acute Treatment/Rescue Medication
Medications for acute treatment of migraine listed above may be taken during the study 
within the parameters noted in Section 4.5.1 for patients taking ubrogepant. 
 
 
 
 
 
 
 
 
 
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
20
GDD-TA-T-004 v2015.10
4.5.1.2
Definition of Females of Childbearing Potential and/or 
Acceptable Contraceptive Methods
For the purposes of this study, females will be considered of childbearing potential unless 
they are naturally postmenopausal (ie, no menses for 2 years) or permanently sterilized 
(ie, bilateral tubal ligation, bilateral salpingectomy, bilateral oophorectomy or hysterectomy).
For WOCBP who may participate in the study, the following methods of contraception, if 
properly used, are generally considered reliable:  hormonal contraceptives (ie, oral, patch, 
vaginal ring, injection, implant), male condom with intravaginal spermicide, diaphragm or 
cervical cap with spermicide, intrauterine device, vasectomized partner, or sexual abstinence.
For males who may participate in the study, the following methods of contraception, if 
properly used, are generally considered reliable: postbilateral vasectomy, barrier 
contraception, or sexual abstinence. Male participants must also refrain from donating sperm 
during the course of the study.
The investigator and each patient will determine the appropriate method of contraception for 
the patient during participation in the study.
If a female becomes pregnant during the study, the investigator will notify Allergan 
immediately after the pregnancy is confirmed, and the patient will be withdrawn from the 
study after appropriate safety follow-up. The investigator will (1) notify the patient’s 
physician that the patient was being treated with investigational drug ubrogepant, and 
(2) follow the progress of the pregnancy. The investigator must document the outcome of the 
pregnancy and provide a copy of the documentation to Allergan.
4.5.2
Prohibited Medications/Treatments
The following medications are prohibited throughout the study period for patients taking 
ubrogepant. Note that for patients assigned to the usual-care arm, these restrictions do not 
apply.

strong and moderate cytochrome P450 3A4 (CYP3A4) inhibitors, including but not 
limited to: systemic (oral/IV) itraconazole, ketoconazole, fluconazole, erythromycin, 
clarithromycin, telithromycin, diltiazem, verapamil, aprepitant, cyclosporine, 
nefazodone, cimetidine, quinine, and human immunodeficiency virus (HIV) protease 
inhibitors

strong and moderate CYP3A4 inducers, including but not limited to: barbiturates (eg, 
phenobarbital and primidone), systemic (oral/IV) glucocorticoids, nevirapine, 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
21
GDD-TA-T-004 v2015.10
efavirenz, pioglitazone, carbamazepine, phenytoin, rifampin, rifabutin, and St. John’s 
wort

inhibitors of the breast cancer resistance protein (BCRP) transporter (eg, rifampin)

drugs with narrow therapeutic margins (eg, digoxin, warfarin)
Examples of prohibited medications in the classes noted above are displayed in 
Attachment 12.2.
The decision to administer a prohibited medication/treatment is done with the safety of the 
study participant as the primary consideration. When possible, Allergan should be notified 
before the prohibited medication/treatment is administered.
4.5.3
Special Diet or Activities
Patients taking ubrogepant must refrain from consuming grapefruit or grapefruit juice from 
the time the consent form is signed until completion of the study. In addition, patients will be 
asked to refrain from sleeping and from consuming caffeine for at least 2 hours after they 
take IP.
Alcohol intake should be limited to no more than 3 drinks per day throughout the study. A 
drink is defined as a 12-ounce can/bottle of beer, a 4-ounce glass of wine, or 1 ounce of 
liquor.
5.
Study Treatments
5.1
Study Treatments and Formulations
Ubrogepant 
 oral compressed tablets containing 50 mg of 
ubrogepant.
Ubrogepant placebo
 tablets.
5.2
Control Treatment
This study does not include a control treatment.
5.3
Methods for Masking/Blinding
Ubrogepant will be provided to patients in the ubrogepant arms. A modified double-dummy 
design will be used to maintain the study blind for the ubrogepant arms. Patients randomized 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
22
GDD-TA-T-004 v2015.10
to the ubrogepant arms will be provided IP in identical blister cards to maintain the blinding, 
and instructed to take 2 tablets to treat their migraine attack regardless of the dose group to 
which they are assigned. The patients randomized to the usual-care arm will not be dispensed 
ubrogepant.
5.4
Treatment Allocation Ratio 
Patients will be randomized (1:1:1) to 1 of the following 3 treatment groups: usual-care, 
ubrogepant 50 mg, or ubrogepant 100 mg. The study is open-label; however, randomization 
to the ubrogepant arms (50 and 100 mg) will be blinded. If and when an interim analysis 
occurs, the doses will be unblinded (see Section 7.6).
 
 
 
5.5
Method for Assignment to Treatment Groups/Randomization
Prior to initiation of study treatment, each patient who provides informed consent will be 
assigned a patient number that will serve as the patient identification number on all study 
documents.
At the time of randomization (ie, Visit 2), eligible patients will be randomly assigned to 1 of 
3 treatment arms in a 1:1:1 ratio to receive usual-care, ubrogepant 50 mg, or ubrogepant 
100 mg or 
 
.
An automated interactive web response system (IWRS) will be used to manage the 
randomization and treatment assignment. Allergan Biostatistics (randomization programmer) 
will prepare the randomization codes.
Investigational product will be labeled with medication kit numbers. The IWRS will provide 
the site with the specific medication kit number(s) for each randomized patient in the 
ubrogepant arms at the time of randomization. Sites will dispense IP according to the IWRS 
instructions. Sites will receive the IWRS confirmation notifications for each transaction. All 
notifications will be maintained with the study source documents.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
23
GDD-TA-T-004 v2015.10
5.6
Treatment Regimen and Dosing
5.6.1
Ubrogepant
Table 2 presents the treatments that will be administered in this study. Patients randomized to 
the ubrogepant arms will be instructed to take 2 tablets to treat their migraine attack 
regardless of the dose group to which they are assigned.
Table 2
Treatments Administered for Initial and Optional Second Dose
Drug/Dose
Dose Frequency
Route of 
Administration
Investigational Product Administered
Initial Dose
Optional Second Dose
Ubrogepant 
50 mg
Up to 8 times/4 weeks for 
1 year (with optional 
second dose – maximum 
16 times/4 weeks)
Oral (tablet)
Ubrogepant 50 mg/ 
placebo 50 mg
Ubrogepant 50 mg/ 
placebo 50 mg
Ubrogepant 
100 mg
Up to 8 times/4 weeks for 
1 year (with optional 
second dose – maximum 
16 times/4 weeks)
Oral (tablet)
Ubrogepant 50 mg/ 
ubrogepant 50 mg
Ubrogepant 50 mg/ 
ubrogepant 50 mg
Patients randomized to the ubrogepant arms will be allowed to treat up to 8 qualifying 
migraine headaches (of any pain severity) per 4-week period throughout the course of a year. 
Patients will be instructed to treat the migraine headaches as soon as possible when all of the 
following conditions are met:

At least 48 hours since the last dose of ubrogepant

At least 48 hours of pain freedom (ie, no headache for at least 48 hours) 

The migraine headache started less than 4 hours ago

The migraine headache is not already resolving on its own

Prohibited medication has not been taken
5.6.2
Usual Care
Patients randomized to the usual-care arm will be instructed to treat their migraine with the 
medication(s) that they routinely take to relieve a migraine attack. Their usual medication(s) 
for acute treatment will be identified at Visit 1. At any time during the study, the patient’s 
treating physician or the investigator may instruct these patients to change their migraine 
treatment. Any changes to the usual medication(s) identified at Visit 1 will be recorded in the 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
24
GDD-TA-T-004 v2015.10
eCRF. There will be no limitations to the number of migraines treated and no qualifiers to 
treat a migraine for patients in this arm. 
5.6.3
Optional Second Dose and Rescue Medication
Patients who took ubrogepant for their initial dose will have the opportunity to take an 
optional second dose of ubrogepant if they continue to have headache of any pain severity or 
if headache (of any pain severity) returns. An optional second dose can be taken from 2 to 
48 hours after the initial ubrogepant dose. 
 
 
 
 
 
 
 
 
 
 
 
 
5.7
Storage of Investigational Products/Treatments
Investigational product at the site must be stored at room temperature in a securely locked 
cabinet. Further details regarding the storage of the IP are in the Study Reference Manual.
6.
Response Measures and Summary of Data Collection Methods
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
25
GDD-TA-T-004 v2015.10
 
 
 
 
 
 
 
 
.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
26
GDD-TA-T-004 v2015.10
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
6.2
Safety Measures
6.2.1
Adverse Events
Subjective AEs will be collected throughout the study. For all AEs, the investigator must 
provide an assessment of the severity, causal relationship to the IP, start and stop date, and 
seriousness of the event (eg, serious adverse event [SAE]), document all actions taken with 
regard to the IP, and detail any other treatment measures taken for the AE. For events noted 
as SAEs, Allergan must be notified immediately to meet their reporting obligations to 
appropriate regulatory authorities (see Section 9.3). 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
27
GDD-TA-T-004 v2015.10
6.2.2
Events of Clinical Interest
Selected nonserious and serious events are of clinical interest and will require immediate 
reporting, recording and follow-up. The following events will be closely monitored:

Suicidal ideations with intent, with or without a plan, (ie, Type 4 or 5 on the C-SSRS) 
or any suicidal behaviors 

Elevated ALT or AST laboratory value that is ≥ 3 times the ULN

Potential Hy’s law cases: elevated ALT or AST laboratory value that is ≥ 3 times the 
ULN and an elevated total bilirubin laboratory value that is ≥ 2 times the ULN and, at 
the same time, an alkaline phosphatase laboratory value that is < 2 times the ULN.
Reporting requirements for ALT or AST elevations and potential Hy’s law cases are outlined 
in Sections 9.5 and 9.6. Responses to the C-SSRS that meet the above criterion will be 
captured in the electronic tablet (eTablet) and monitored by Allergan. Events that are 
determined to be AEs or SAEs must be reported appropriately via the designated eCRF pages 
and forms.
6.2.3
Clinical Laboratory Determinations
Blood and urine samples for clinical laboratory tests will be collected at the visits outlined in 
Table 1. Hematology, chemistry, and urinalysis will be conducted at these visits. The 
investigator will assess the clinical significance of any values outside the reference ranges 
provided by the central laboratory. A central laboratory will be used to evaluate all urine and 
blood samples, which will be collected, processed, and stored according to the instructions 
provided by the laboratory. Patients with abnormalities judged to be clinically significant at 
Screening (Visit 1) will be excluded from the study. WOCBP will be required to have a urine 
pregnancy test at all visits. A positive pregnancy test at Visit 1 or Visit 2 will exclude the 
patient from participation in the study. Investigators may also perform unscheduled clinical 
laboratory determinations at any time for the purpose of patient safety. Patients are not 
required to fast overnight before coming in for their appointments. 
The clinical laboratory parameters to be measured are shown in Table 3.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
28
GDD-TA-T-004 v2015.10
Table 3
Clinical Laboratory Parameters
Category
Parameter
Chemistry
Sodium, potassium, chloride, bicarbonate, glucose, blood urea nitrogen, 
creatinine, total bilirubin, alkaline phosphatase, aspartate aminotransferase, 
alanine aminotransferase, lactate dehydrogenase, creatine kinase, total protein, 
albumin, calcium, phosphorus, uric acid, total cholesterol, high density 
lipoprotein, low density lipoprotein, total triglycerides; the estimated glomerular 
filtration rate will be calculated by the central laboratory
Hematology
Hemoglobin; hematocrit; red blood cell count; red blood cell indices (mean 
corpuscular volume, mean corpuscular hemoglobin, mean corpuscular 
hemoglobin concentration); white blood cell count, including differential 
(neutrophils, lymphocytes, monocytes, eosinophils, and basophils); platelet count
Urinalysis
Urine dipstick for specific gravity, pH, protein, glucose, ketones, bilirubin, and 
blood; microscopic examination including red blood cells/high-power field, 
white blood cells/high-power field, and casts/low-power field
6.2.4
Vital Sign Measurements
Vital sign measurements, including sitting and standing BP, sitting and standing pulse rate, 
respiratory rate, temperature, and body weight will be taken, according to Table 1. Sitting 
and standing BP and pulse rate will be determined as follows: BP and pulse measurements 
will be performed after the patient sits quietly for 5 minutes, followed by a second set of 
measurements taken after the patient stands for 3 minutes (but no longer than 10 minutes).
6.2.5
Physical Examinations
A complete physical examination will be performed at the visits outlined in Table 1. A 
professionally trained physician or healthcare professional licensed to performed physical 
examinations will examine the patient for any detectable abnormalities of the following body 
systems: general appearance; neck (including thyroid); head, eyes, ears, nose, and throat; 
lungs; heart/cardiovascular; abdomen; neurologic; extremities; back; musculoskeletal; 
lymphatic; skin; and other. The neurologic examination should be conducted to detect the 
presence of any significant sensory/motor abnormalities.
6.2.6
Electrocardiograms
A 12-lead ECG will be performed at the visits outlined in Table 1. ECGs will be sent to a 
central ECG laboratory to be centrally read by a cardiologist. All ECGs should be performed 
after the patient has been supine for at least 5 minutes. A copy of the ECG will be saved as a 
source document. ECGs will be transmitted electronically to the central ECG laboratory for 
analysis according to the instructions provided by the laboratory. The overall interpretation 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
29
GDD-TA-T-004 v2015.10
of the clinical significance of the ECG will be determined by the investigator and recorded in 
the patient’s eCRF in the source notes.
6.2.7
Suicidality Assessment
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation 
and behavior. Suicidal ideation is classified on a 5-item scale: Type 1 (wish to be dead), Type 
2 (nonspecific active suicidal thoughts), Type 3 (active suicidal ideation with any methods 
[not plan] without intent to act), Type 4 (active suicidal ideation with some intent to act, 
without specific plan), and Type 5 (active suicidal ideation with specific plan and intent). The 
C-SSRS also captures information about the intensity of ideation, specifically the frequency, 
duration, controllability, deterrents, and reasons for the most severe types of ideation. 
Suicidal behavior is classified on a 5-item scale: Type 0 (no suicidal behavior), Type 1 
(preparatory acts or behavior), Type 2 (aborted attempt), Type 3 (interrupted attempt), and 
Type 4 (actual attempt). More than 1 classification can be selected provided they represent 
separate episodes. For actual attempts only, the actual or potential lethality is classified for 
the initial, most lethal, and most recent attempts. The C-SSRS will be completed at all study 
visits. At all visits, the C-SSRS will be completed for ideation and behavior since the 
previous visit. The C-SSRS will be completed on the eTablet by the investigator or designee 
with current and valid training in administering the assessment. A patient should not be 
released from the study center until the results of C-SSRS are reviewed and it is confirmed 
that the patient is not considered to be at risk.
6.2.8
Cardiovascular Disease Risk
Patients will be classified to 1 of 3 coronary heart disease risk categories (low, moderate, 
high) based on the National Cholesterol Education Program (NCEP; NIH Publication 
No. 01-3670, 2001). 

Category 1 (High Risk): > 20% 10-year cardiovascular (CV) risk 

Category 2 (Moderate Risk): 10 to 20% 10-year CV risk 

Category 3 (Low Risk): < 10% 10-year CV risk
Risk of cardiovascular disease will be assessed in the lead-in studies using an algorithm 
based on NCEP and the Framingham risk factors, along with the presence of cardiovascular 
heart disease or other clinical forms of atherosclerotic disease, as well as diabetes.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
30
GDD-TA-T-004 v2015.10
6.3
Other Study Supplies
The following will be provided by Allergan:

All supplies needed for blood and urine sampling (central laboratory analysis, urine 
culture/sensitivity), urine dipstick reagent strips, and urine pregnancy tests

Shipping materials for shipment of laboratory samples to central laboratory

All supplies needed for ECG assessment, including ECG machine

eDiary

eTablet
6.4
Summary of Methods of Data Collection
An IWRS will be used to randomize patients and manage ubrogepant inventory. Data for this 
study will be collected using eCRFs via an electronic data capture system. Source documents 
will be used at the sites and may include a patient’s medical record, hospital charts, clinic 
charts, the investigator’s patient study files, as well as the results of diagnostic tests, such as 
laboratory tests, ECGs, etc. Centralized vendors will be used for the analysis of all 
blood/urine samples and ECG assessments. Additional information on the collection and 
handling of samples is detailed in respective laboratory manuals. 
Patients in the ubrogepant arms will use an eDiary to record details associated with their 
migraine attack, 
 
. Patients in the usual-care arm will 
use the eDiary to record details associated with their migraine attack before it is treated with 
their usual medication.
The C-SSRS will be conducted as a clinical interview at each visit and recorded by a 
qualified site staff member via an eTablet.
7.
Statistical Procedures
7.1
Analysis Populations
7.1.1
Modified Intent-to-Treat Population
The Modified Intent-to-Treat (mITT) population will consist of all randomized patients who 
received at least 1 dose of IP (ubrogepant) and had at least 1 post-treatment efficacy 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
31
GDD-TA-T-004 v2015.10
assessment in this study. The mITT population is only defined for the ubrogepant arms, as no 
efficacy measurements will be collected from patients in the usual-care arm.
7.1.2
Safety Population
The Safety population will be defined separately for the ubrogepant arms and the usual-care 
arm. 

Ubrogepant arms: All randomized patients who received ≥ 1 dose of treatment 

Usual-care arm: All randomized patients in the usual-care arm. 
The purpose of the usual-care arm is to contextualize any safety findings that may occur in 
the ubrogepant treated patients over the course of 12 months.  As such, data from all patients 
randomized to the usual-care arm, regardless of whether the patient used medication to treat 
migraine, will be included in the safety analyses.
 
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
32
GDD-TA-T-004 v2015.10
 
 
 
 
 
 
 
 
7.3
Hypothesis and Methods of Analysis
 
 
 
 
.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
33
GDD-TA-T-004 v2015.10
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3.2
Safety Analyses
The safety analyses will be performed using the Safety population. The safety parameters 
will include AEs, clinical laboratory evaluations, vital sign measurements, ECG parameters, 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
34
GDD-TA-T-004 v2015.10
and the C-SSRS. For each of the clinical, laboratory, vital sign, and ECG parameters, the last 
nonmissing safety assessment before the first dose in the lead-in study will be used as the 
baseline for all analyses of that safety parameter. Continuous variables will be summarized 
by the number of patients and mean, SD, median, minimum, and maximum values. 
Categorical variables will be summarized by number and percentage of patients.
7.3.2.1
Adverse Events
AEs will be coded by system organ class and preferred term using the Medical Dictionary for 
Regulatory Activities. 
An AE will be considered a treatment-emergent adverse event (TEAE) if it was present after 
the first dose of treatment in the lead-in study or was present before the date of the first dose 
of treatment in the lead-in study and increased in severity after the first dose of treatment in 
the lead-in study. If more than 1 AE was reported before the first dose of treatment of the 
lead-in study and coded to the same preferred term, the AE with the greatest severity will be 
used for comparison with the AEs occurring after the first dose of treatment of the lead-in 
study. An AE that occurs after Visit 16 for patients with Visit 16, or more than 30 days after 
the last visit or last treatment, whichever is later, for patients without Visit 16 will not be 
considered as a TEAE. 
The number and percentage of patients reporting TEAEs after randomization in each 
treatment group will be tabulated by descending percentage in the highest dose group, by 
system organ class and preferred term, and further categorized by severity and causal 
relationship to the study treatment. If more than 1 AE is coded to the same patient, the patient
will be counted only once for that preferred term using the greatest severity and strictest 
causality for the summarization by severity and causal relationship. 
The incidence of common (≥ 2% of patients in any treatment group) TEAEs will be 
summarized by system organ class, preferred term, and treatment group. 
The total number of TEAEs by severity and causal relationship to the study treatment will be 
summarized by treatment group. 
A SAE that occurred between the date of the first dose of treatment in the lead-in study and 
Visit 16 for patients with Visit 16, or within 30 days after the last visit or last treatment, 
whichever is later, for patients without Visit 16, inclusive, will be considered an on-therapy 
SAE. The number and percentage of patients who have on-therapy SAEs after randomization 
will be summarized by preferred term and treatment group. 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
35
GDD-TA-T-004 v2015.10
The number and percentage of patients who had AEs leading to premature discontinuation of 
the study treatment will be summarized by preferred term and treatment. 
For all screened patients, separate tabular displays will be presented for patients who died, 
patients with SAEs, and patients with AEs leading to premature discontinuation. 
The number and percentage of patients with TEAEs of clinical interest will be summarized 
by preferred term and treatment group. TEAEs of clinical interest include triptan-associated 
TEAEs, abuse-related TEAEs, hepatic injury TEAEs, cardiac arrhythmias TEAEs, central 
nervous system TEAEs, vascular disorders TEAEs, embolic and thrombotic events TEAEs, 
hypertension TEAEs, ischemic heart disease TEAEs, and suicide/self-injury TEAEs.
7.3.2.2
Cardiovascular Risk
Patients will be categorized into 1 of 3 coronary heart disease (CHD) risk subgroups based 
on National Cholesterol Education Program Adult Treatment Panel III Guidelines (NCEP 
ATP III) (Grundy 2004; NIH Publication No. 01-3670, 2001). An algorithm will be used for 
assigning patients to a CV risk category (low, moderate, or high risk) in the lead-in studies.
A summary of adverse experiences will be provided for the CV risk factor subgroups listed 
above. 
7.3.2.3
Clinical Laboratory Parameters
Descriptive statistics for clinical laboratory values (in SI units) and changes from the baseline 
values at each assessment timepoint will be presented by treatment group for clinical 
laboratory parameters. In addition, descriptive statistics for values and changes from the 
baseline values in conventional units at each assessment timepoint will be presented for 
selected clinical laboratory parameters. Patient narratives will also include the values in 
conventional units for the selected laboratory parameters. 
Clinical laboratory test values will be considered potentially clinically significant (PCS) if 
they meet either the lower-limit or higher-limit PCS criteria. PCS criteria will be specified in 
the Statistical Analysis Plan (SAP). The number and percentage of patients who have PCS 
postbaseline clinical laboratory values will be tabulated by treatment group. The percentages 
will be calculated relative to the number of patients with available non-PCS baseline values 
and at least 1 postbaseline assessment. The numerator will be the total number of patients 
with available non PCS baseline values and at least 1 PCS postbaseline value. A supportive 
tabular display of patients with PCS postbaseline values will be provided, including the 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
36
GDD-TA-T-004 v2015.10
patient number, baseline, and all postbaseline (including non-PCS) values. In addition, a 
tabular display showing all AEs that occurred in patients who had PCS postbaseline clinical 
laboratory values will be provided.
Shift tables from baseline to end of study for clinical laboratory parameters will be presented 
by treatment group for the following categories: low, normal, and high, which are provided 
by the lab vendor.
Any post-treatment ALT and/or AST results that are ≥ 3 times the ULN are considered 
events of clinical interest in this study and are subject to blinded adjudication by the Clinical 
Adjudication Committee to determine whether the elevation is due to treatment or not, and to 
determine whether there is a confounding factor. Patients with liver function laboratory 
findings that meet predetermined criteria will be summarized by treatment group along with 
the adjudication results. A detailed listing of all patients with any liver function laboratory 
findings will be provided.
7.3.2.4
Vital Sign Measurements
Descriptive statistics for vital sign measurements (sitting and standing systolic and diastolic 
BP, sitting and standing pulse rate, respiratory rate, temperature, weight, and BMI) and 
changes from baseline values at each visit and at the end of study will be presented by 
treatment group.
Vital sign values will be considered PCS if they meet both the observed-value criteria and the 
change-from-baseline criteria. PCS criteria will be specified in the SAP. The number and 
percentage of patients with PCS postbaseline values will be tabulated by treatment group. 
The percentages will be calculated relative to the number of patients with available non-PCS 
baseline values and at least 1 postbaseline assessment. The numerator will be the total 
number of patients with available non-PCS baseline values and at least 1 PCS postbaseline 
value. A supportive tabular display of patients with PCS postbaseline values will be 
provided, including the patient number, baseline and all postbaseline (including non-PCS) 
values.
In addition, a tabular display showing all AEs that occurred in patients who had PCS 
postbaseline vital sign values will be provided.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
37
GDD-TA-T-004 v2015.10
7.3.2.5
Electrocardiogram
Descriptive statistics for ECG parameters (heart rate, RR interval, PR interval, QRS interval, 
QT interval, and QTc) and changes from baseline values at each assessment timepoint to the 
end of study will be presented by treatment group. 
Electrocardiographic parameter values are considered PCS if they meet or exceed the 
higher-limit PCS criteria. PCS criteria will be specified in the SAP. The number and 
percentage of patients with PCS postbaseline ECG values will be tabulated by treatment 
group. The percentages will be calculated relative to the number of patients with available 
non-PCS baseline values and at least 1 postbaseline assessment. The numerator is the total 
number of patients with available non-PCS baseline values and at least 1 PCS postbaseline 
value. A supportive tabular display of patients with PCS postbaseline values will be 
provided, including the patient number, baseline, all postbaseline (including non-PCS) 
values, and change from baseline. In addition, a tabular display showing all AEs that 
occurred in patients who had postbaseline PCS ECG values will be provided.
A shift table from baseline to the end of study in the investigator’s overall interpretation of 
the ECG will be presented by treatment group for the following categories: normal,
abnormal, not clinically significant, abnormal, clinically significant. A tabular display 
showing patients with postbaseline clinically significant ECG abnormalities according to the 
investigator’s overall interpretation will be provided.
7.3.2.6
Suicidality Assessment
For the C-SSRS, the number of patients with suicidal ideation and suicidal behavior in 
lifetime history, during the treatment period, and during the Safety Follow-up period will be 
summarized by treatment group for the Safety population. Supportive tabular display of 
patients with all values will be provided, including patient number, treatment group, visit 
number, intensity of suicidal ideation, suicidal behavior type, and lethality of suicidal 
behavior. 
7.3.2.7
Potential Hy’s Law
Potential Hy’s Law criteria within a 24-hour window is defined by a postbaseline elevation 
of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3 times the ULN, 
along with total bilirubin (TBL) ≥ 2 times the ULN and a nonelevated alkaline phosphatase 
(ALP) < 2 times the ULN, all based on blood draws collected within a 24-hour period.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
38
GDD-TA-T-004 v2015.10
Potential Hy’s Law criteria without time window (evaluation of drug-induced serious 
hepatotoxicity [eDISH]) is defined by maximum of postbaseline elevation of ALT or AST 
≥3 times the ULN, along with maximum of postbaseline elevation of TBL ≥ 2 times the 
ULN.
Patients who meet the potential Hy’s Law criteria from randomization to Visit 16 will be 
summarized. Supportive tabular displays also will be provided. 
7.4
Subgroup Analyses
Subgroup analyses will be done for disposition, treatment exposure, and TEAEs for sex, age 
group (< 40 vs ≥40, and < 65 vs ≥65), race (white vs all other races), cardiovascular risk 
category, and renal function class.
 
 
 
 
 
 
7.6
Interim Analyses
The interim analysis for Study UBR-MD-04 will occur when at least 300 ubrogepant patients
(with a minimum of 2 migraines treated with ubrogepant per month, on average) have been 
enrolled in Study UBR-MD-04 for 6 months and 200 ubrogepant patients (with a minimum 
of 2 migraines treated with ubrogepant per month, on average) have been enrolled in 
Study UBR-MD-04 for 1 year. 
In regards to blinding, although this is an open-label study, randomization to the ubrogepant 
50 mg or 100 mg arms is blinded. If and when an interim analysis occurs, Allergan staff will 
be unblinded to the ubrogepant doses; however, patients and sites will remain blinded. The 
interim analysis will include all analyses specified in the SAP except for efficacy analyses.
Details regarding the interim analysis are specified in the SAP.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
39
GDD-TA-T-004 v2015.10
8.
Study Visit Schedule and Procedures
Table 1 presents the schedule of visits and procedures. 
8.1
Patient Entry Procedures
8.1.1
Overview of Entry Procedures
Prospective patients as defined by the inclusion and exclusion criteria in Sections 4.3 and 4.4
who completed Study UBR-MD-01 or UBR-MD-02 will be considered for entry into this 
study.
8.1.2
Informed Consent and Patient Privacy
The study will be discussed with the patient and a patient wishing to participate must give 
informed consent prior to any study-related procedures or change in treatment. The patient 
must also give authorization and other written documentation in accordance with local 
privacy requirements (where applicable) prior to any study-related procedures or change in 
treatment.
Each patient that provides informed consent will continue using the patient number assigned 
in the lead-in study for documentation throughout the study.
 
 
 
 
 
 
 
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
40
GDD-TA-T-004 v2015.10
and
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
41
GDD-TA-T-004 v2015.10
 
 
 
 
 
 
 
 
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
42
GDD-TA-T-004 v2015.10
 
 
 
 
 
 
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
43
GDD-TA-T-004 v2015.10

 
 
 
 
 
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
44
GDD-TA-T-004 v2015.10
 
8.5
Instructions for the Patients
Section 4.5.3 provides diet and activity instructions for patients enrolled in the study. 
All patients will be instructed to use an electronic diary (eDiary) to record details associated 
with their migraine attack. Training for the eDiary will be provided for qualified patients at 
Visit 2. Patients will be instructed to bring their eDiary to each clinic visit and for those who 
were dispensed ubrogepant, return their medication packs (used and unused).
8.6
Unscheduled Visits
Additional examinations and laboratory assessments may be performed as necessary to 
ensure the safety and well-being of the patients during the study period. Unscheduled visit 
eCRFs should be completed for each unscheduled visit. For all parameters not measured, 
indicate “not done”.
8.7
Compliance with Protocol
All assessments will be conducted at the appropriate visits as outlined in Table 1, and the 
timing of the visits should occur as close as possible to the specified day. At each visit, the 
patient will be asked if he or she changed the dose/regimen of any existing concomitant 
medications or initiated the use of any new concomitant medications since the last visit, to 
ensure compliance with the protocol.
Patients will record the requested information regarding their migraine attack and ubrogepant 
taken in the eDiary. Ubrogepant compliance will be closely monitored by counting the 
number of tablets dispensed and returned. Every effort will be made to collect all unused 
ubrogepant.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
45
GDD-TA-T-004 v2015.10
8.8
Early Discontinuation of Patients
A premature discontinuation will occur when a patient who signed the informed consent 
form (ICF) and was randomized ceases participation in the study, regardless of 
circumstances, before completion of the study. Patients can be prematurely discontinued 
from the study for 1 of the following reasons:

AE

Protocol violation

Noncompliance with ubrogepant

Withdrawal of consent (a clear reason must be documented)

Lost to follow-up (every effort must be made to contact the patient; a 
certified/traceable letter must be sent)

Lack of qualifying event (a qualifying migraine is not treated within 6 months)

Pregnancy

Other reasons
Patients may voluntarily withdraw from the study at any time. Notification of early patient 
discontinuation from the study and the reason for discontinuation will be made to Allergan 
and will be clearly documented on the appropriate eCRF. All randomized patients who 
prematurely discontinue from the study, regardless of cause, should be seen for a final 
assessment. A final assessment will be defined as completion of the evaluations scheduled 
for Visit 15/ ET. If the patient discontinues prematurely, the patient is expected to return for a 
Safety Follow-up visit 4 weeks after Visit 15/ET.
8.9
Withdrawal Criteria
Women who become pregnant will be withdrawn from the study (see Section 4.5.1.2) and 
should refrain from taking ubrogepant. The patient should return to the clinic for Visit 15/ET 
procedures.
Patients who meet IP discontinuation criteria related to abnormal liver function tests 
(Section 9.5) and who are advised not to be re-challenged will be withdrawn from the study.
Patients who reply with “yes” to questions 4 or 5 in the suicidal ideation section or “yes” to 
any question in the suicidal behavior section of the C-SSRS should not receive any further 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
46
GDD-TA-T-004 v2015.10
ubrogepant, must be withdrawn from the study, and should receive appropriate follow-up as 
in routine clinical practice, including the Safety Follow-up visit (Visit 16) if ubrogepant was 
taken.
A patient with a condition and/or a situation that, in the investigator's opinion, may put the 
patient at significant risk, may confound the study results, or may interfere significantly with 
the patient's participation in the study may be withdrawn from treatment.
8.10
Study Termination
Allergan may stop the study (and/or the study site) for any reason with appropriate 
notification.
9.
Adverse Events
AEs occurring during the study will be recorded on an AE eCRF. If AEs occur, the first 
concern will be the safety of the study participants.
9.1
Definitions
9.1.1
Adverse Event
An AE is any untoward medical occurrence in a patient or clinical investigation patient 
administered a pharmaceutical product and that does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with 
the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product. In addition, during the screening period, AEs will be assessed 
regardless of the administration of a pharmaceutical product.
Note:  AEs must be collected once informed consent has been obtained, regardless of 
whether or not the patient has been administered study drug.
Progression of treatment indication including new or worsening of anticipated clinical signs 
or symptoms, which are collected as clinical efficacy variables and assessed as unequivocally 
associated with the disease progression and/or lack of efficacy, should NOT be reported as 
AEs unless the disease progression is greater than anticipated in the natural course of the 
disease.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
47
GDD-TA-T-004 v2015.10
AEs will be assessed, documented, and recorded in the eCRF throughout the study (ie, after 
informed consent has been obtained). At each visit, the investigator will begin by querying 
for AEs by asking each patient a general, non-directed question such as “How have you been 
feeling since the last visit?” Directed questioning and examination will then be done as 
appropriate. All reported AEs will be documented on the appropriate case report form.
9.1.2
Serious Adverse Event
An SAE is any AE occurring at any dose that results in any of the following outcomes: death, 
a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a 
persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Important 
medical events that may not result in death, be life-threatening, or require hospitalization 
may be considered an SAE when, based upon appropriate medical judgment, they may 
jeopardize the patient, or the patient may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition. See Section 9.3 for procedures for reporting an 
SAE.
Allergan considers all cancer AEs as SAEs. In addition, Allergan considers any abortion 
(spontaneous or nonspontaneous) as an SAE.
Preplanned surgeries or procedures for pre-existing, known medical conditions for which a 
patient requires hospitalization are not reportable as SAEs.
Any preplanned surgery or procedure should be clearly documented in the site source 
documents by the medically qualified investigator at the time of the patient’s entry into the 
study. If it has not been documented at the time of the patient’s entry into the study, then it 
should be documented as an SAE and reported to Allergan.
9.1.3
Severity
A clinical determination will be made of the intensity of an AE. The severity assessment for 
a clinical AE must be completed using the following definitions as guidelines:
Mild
Awareness of sign or symptom, but easily tolerated
Moderate
Discomfort enough to cause interference with usual activity
Severe
Incapacitating with inability to work or do usual activity

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
48
GDD-TA-T-004 v2015.10
9.1.4
Relationship to Study Drug or Study Procedure
A determination will be made of the relationship (if any) between an AE and the study drug 
or study procedure, as applicable. A causal relationship is present if a determination is made 
that there is a reasonable possibility that the AE may have been caused by the drug or study 
procedure.
9.2
Procedures for Reporting Adverse Events
Any AE must be recorded on the appropriate eCRF.
All SAEs that are drug-related and unexpected (not listed as treatment-related in the current 
Investigator's Brochure) must be reported to the governing Institutional Review 
Board/Independent Ethics Committee (IRB/IEC) as required by the IRB/IEC, local 
regulations, and the governing health authorities. Any AE that is marked “ongoing” at the 
exit visit must be followed-up as appropriate.
9.3
Procedures for Reporting a Serious Adverse Event
Any SAE occurring during the study period (beginning with informed consent) and for at 
least 30 days after the last dose of study drug must be immediately reported no later than 
24 hours after learning of an SAE. SAEs must be reported to Allergan or Agent of Allergan 
(eg, contract research organization [CRO]) and recorded on the SAE form. All patients with 
an SAE must be followed up and the outcomes reported. The investigator must supply 
Allergan and the IRB/IEC with any additional requested information (eg, autopsy reports and 
discharge summaries).
In the event of an SAE, the investigator must:
1. Notify Allergan immediately by fax or email using the SAE form (contact details can 
be found on page 1 of the SAE form); the fax number is on the front page of this 
protocol, and phone numbers and relevant Allergan personnel contacts are also on the 
study contacts page.
2. Obtain and maintain in his/her files all pertinent medical records, information, and 
medical judgments from colleagues who assisted in the treatment and follow-up of 
the patient.
3. Provide Allergan with a complete, written description of the AE(s) on the SAE form 
describing the event chronologically, including any treatment given (eg, medications 
administered, procedures performed) for the AE(s). Summarize relevant clinical 
information about the event: signs, symptoms, diagnosis, clinical course and relevant 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
49
GDD-TA-T-004 v2015.10
clinical laboratory tests, etc. Include any additional or alternative explanation(s) for 
the causality which includes a statement as to whether the event was or was not 
related to the use of the investigational drug.
4. Promptly inform the governing IRB/IEC of the SAE as required by the IRB/IEC, 
local regulations, and the governing health authorities.
9.4
Exposure to Investigational Product During Pregnancy
Study center personnel must report every pregnancy (from the time the patient signs the ICF 
for the trial until 30 days after the last dose of ubrogepant), on the Pregnancy Form as soon 
as possible (within 24 hours of learning of the pregnancy) to the SAE/pregnancy fax number, 
 even if no AE has occurred. Pregnancies in female partners of male 
patients must also be reported. The pregnancy must be followed to term, and the outcome 
reported by completing a follow-up Pregnancy Form. If, however, the pregnancy is 
associated with an SAE (eg, if the mother is hospitalized for hemorrhage), in addition to the 
Pregnancy Form, a separate SAE Form must be filed as described in Section 9.3 with the 
appropriate serious criterion (eg, hospitalization) indicated.
9.5
ALT or AST Elevations
A post-treatment event of ALT or AST ≥ 3 times the ULN is considered an Event of Clinical
Interest. Any patient with this laboratory result after ubrogepant was taken should have 
repeat testing within 48 to 72 hours to confirm the abnormality. For this repeat testing, the 
following tests should be performed: hematology and chemistry panels, international 
normalized ratio (INR), and a toxicology screen for acetaminophen. In addition, the 
investigator should perform a complete history and examination to evaluate for possible liver 
disease. 
All ALT or AST elevations ≥ 3 times the ULN must be reported to Allergan using the AE of 
Interest Form and submitted within 24 hours of the time the investigator becomes aware of 
the event. All new elements of history, physical examination, diagnostic testing results, and 
other relevant medical reports are to be reported for each event.
If an ALT or AST elevation ≥ 3 times the ULN is confirmed and the patient meets any 
of the following criteria, close medical follow-up is required:

Patients with ALT or AST ≥ 3 times ULN and ≤ 5 times the ULN and who are 
asymptomatic with regard to possible liver disease (ie, no fatigue, nausea, vomiting, 
right upper quadrant pain or tenderness, fever, rash, or eosinophilia [> 5%])

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
50
GDD-TA-T-004 v2015.10

Patients with ALT or AST ≥ 3 times ULN and ≤ 5 times the ULN and (total bilirubin 
< 2 times the ULN and INR < 1.5)
Patients who meet these criteria should be followed clinically, and further medical evaluation 
should be performed per the judgment of the investigator and in conjunction with medical 
personnel at Allergan. The chemistry panel should be repeated 1 to 2 times per week to 
follow the course of ALT/AST elevation. An extra blood sample should be collected and sent 
to the central laboratory for further diagnostic testing at a later date if needed.
If an ALT or AST elevation ≥ 3 times the ULN is confirmed and the patient meets any 
of the following criteria, close medical follow-up is required:

ALT or AST ≥ 3 times the ULN and the patient is symptomatic with the appearance 
of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or 
eosinophilia (> 5%)

ALT or AST ≥ 3 times the ULN and total bilirubin > 2 times the ULN or INR > 1.5

ALT or AST ≥ 5 times the ULN
In addition, for these patients, possible etiologies for acute hepatic injury should be excluded. 
The following laboratory tests should be performed:  anti-hepatitis A IgM, hepatitis B surface 
antigen, anti-hepatitis B core IgM, hepatitis C antibody, hepatitis C quantitative RNA by 
polymerase chain reaction (PCR), anti-hepatitis E IgM. An extra blood sample should be 
collected and sent to the central laboratory for further diagnostic testing at a later date if 
needed. The patient should be followed clinically, and further medical evaluation should be 
done per the judgment of the investigator and in conjunction with medical personnel at 
Allergan. In general, the chemistry panel should be repeated 1 to 2 times per week to follow 
the course of ALT/AST elevation. For procedural details on the medical evaluation of liver 
disease, please see the Study Reference Manual.
The investigator should contact the Allergan Medical Monitor to discuss all cases of 
confirmed ALT/AST elevation ≥ 3 times the ULN. All ALT/AST elevations should be 
followed until ALT and AST return to < 1.5 times the ULN and there is full clinical 
resolution.
Study drug should be discontinued if any of the following criteria are met: 

ALT or AST ≥ 3 times the ULN and the patient is symptomatic with the appearance 
of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or 
eosinophilia (> 5%)

ALT or AST ≥ 3 times the ULN and total bilirubin > 2 times the ULN or INR > 1.5

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
51
GDD-TA-T-004 v2015.10

ALT or AST ≥ 5 times the ULN for more than 2 weeks

ALT or AST ≥ 8 times the ULN
The patient may be rechallenged with ubrogepant upon consultation with the Allergan 
Medical Monitor. If a patient is not rechallenged with IP, the patient must be discontinued 
from the study and complete the ET Visit 15 and Safety Follow-Up Visit 16. Patients should 
receive appropriate follow-up as per standard of care.
9.6
Potential Hy’s Law Cases
Sites must report every patient who meets the following potential Hy’s law criteria if this 
occurs within the time the patient signs the ICF until 30 days after the last dose of 
ubrogepant:

ALT or AST ≥ 3 times the ULN, AND

Total bilirubin ≥ 2 times the ULN, AND

Alkaline phosphatase < 2 times the ULN
A laboratory alert for potential Hy’s laws cases will be in place, and the investigators and 
Allergan will be notified immediately when the above criteria have been met. Any potential 
Hy’s law case should be considered an SAE and also reported as an AE of Special Interest. 
Both the SAE and AE of Interest Forms must be completed as soon as possible (within 
24 hours of learning of the potential Hy’s law) and faxed to the SAE/Pregnancy fax number 
. The eCRF pages associated with potential Hy’s law cases should be 
completed within 7 calendar days. Every effort to determine the cause of the liver 
abnormalities must be made, and close monitoring should be initiated in conjunction with the 
Allergan Medical Monitor and in accordance with the FDA “Guidance for Industry: Drug 
Induced Liver Injury - Pre-Marketing Clinical Evaluation,” dated July 2009 (FDA Guidance 
UCM174090, 2009). For specific instructions, please refer to the Study Reference Manual.
9.7
Procedures for Unmasking of Investigational Product
When necessary for the safety and proper treatment of the patient, the investigator can 
unmask the patient’s treatment assignment to determine which treatment has been assigned 
and institute appropriate follow-up care. When possible, the Allergan Medical Monitor 
should be notified prior to unmasking ubrogepant. The investigator should inform the 
Allergan Medical Monitor of the unmasking if there is no notification prior to the unmasking.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
52
GDD-TA-T-004 v2015.10
The treatment assignment for the patient can be determined by designated site personnel 
logging into the IWRS via password protected access. The reason for breaking the code must 
be recorded in the patient’s source documents.
10.
Administrative Items
This protocol is to be conducted in accordance with the applicable Good Clinical Practice 
(GCP) regulations and guidelines, eg, the International Conference on Harmonisation (ICH) 
Guideline on GCP.
10.1
Protection of Human Patients
10.1.1
Compliance with Informed Consent Regulations (US 21 CFR 
Part 50) and Relevant Country Regulations
Written informed consent is to be obtained from each patient prior to any study-related 
activities or procedures in the study, and/or from the patient's legally authorized 
representative. 
10.1.2
Compliance with IRB or IEC Regulations
This study is to be conducted in accordance with IRB regulations (US 21 CFR Part 56.103) 
or applicable IEC regulations. The investigator must obtain approval from a properly 
constituted IRB/IEC prior to initiating the study and re-approval or review at least annually. 
Allergan is to be notified immediately if the responsible IRB/IEC has been disqualified or if 
proceedings leading to disqualification have begun. Copies of all IRB/IEC correspondence 
with the investigator should be provided to Allergan.
10.1.3
Compliance with Good Clinical Practice
This protocol is to be conducted in accordance with the applicable GCP regulations and 
guidelines.
10.1.4
Compliance with Electronic Records; Electronic Signatures 
10.1.4.1
Regulations (US 21CFR Part 11)
This study is to be conducted in compliance with the regulations on electronic records and 
electronic signature.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
53
GDD-TA-T-004 v2015.10
10.2
Changes to the Protocol
The investigator must not implement any deviation from or changes to the protocol without 
approval by Allergan and prior review and documented approval/favorable opinion from the 
IRB/IEC of a protocol amendment, except where necessary to eliminate immediate hazards 
to study patients, or when the changes involve only logistical or administrative aspects of the 
study (eg, change in monitors, change of telephone numbers).
10.3
Patient Confidentiality
A report of the results of this study may be published or sent to the appropriate health 
authorities in any country in which the study drug may ultimately be marketed, but the 
patients’ names will not be disclosed in these documents. The patients’ names may be 
disclosed to the sponsor of the study, Allergan, or the governing health authorities or the 
FDA if they inspect the study records. Appropriate precautions will be taken to maintain 
confidentiality of medical records and personal information.
10.3.1
Patient Privacy
Written authorization and other documentation in accordance with the local privacy 
requirements (where applicable) is to be obtained from each patient prior to enrollment into 
the study, and/or from the patient's legally authorized representative in accordance with the 
applicable privacy requirements (eg, the Health Insurance Portability and Accountability Act 
Standards for Privacy of Individually Identifiable Health Information [HIPAA]).
In accordance with HIPAA requirements, additional purposes of this study may include 
publishing of anonymous patient data from the study.
10.4
Documentation
10.4.1
Source Documents
Source documents may include a patient's medical records, hospital charts, clinic charts, the 
investigator's patient study files, the eDiary, as well as the results of diagnostic tests, such as 
laboratory tests and electrocardiograms. The investigator's copy of the eCRF serves as part of 
the investigator's record of a patient's study-related data.
The following information should be entered into the patient's medical record:

Patient’s name

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
54
GDD-TA-T-004 v2015.10

Patient’s contact information

The date that the patient entered the study, patient number, and patient randomization 
(or medication kit) number

The study title and/or the protocol number of the study and the name of Allergan

A statement that informed consent was obtained (including the date); a statement that 
written authorization or other local patient privacy required documentation for this 
study has been obtained (including the date)

Dates of all patient visits

All concurrent medications (list all prescription and nonprescription medications 
being taken at the time of enrollment; at each subsequent visit, changes to the list of 
medications should be recorded)

Occurrence and status of any AEs

The date the patient exited the study, and a notation as to whether the patient 
completed the study or reason for discontinuation

The results of laboratory tests performed by the site (eg, results of urine pregnancy 
tests)

Key study variables
Source documentation practices must follow Section 4.0 of ICH E6, Good Clinical Practice: 
Consolidated Guidance and ALCOA, ie, records must be attributable, legible, 
contemporaneous, original, and accurate.
10.4.2
Case Report Form Completion
The investigator is responsible for ensuring that data are properly recorded on each patient's 
case report forms and related documents. An investigator who has signed the protocol 
signature page should personally sign for the case report forms (as indicated in the case 
report forms) to ensure that the observations and findings are recorded on the case report 
forms correctly and completely. The case report forms are to be submitted to Allergan in a 
timely manner at the completion of the study, or as otherwise specified by Allergan and will 
be maintained in a central data repository.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
55
GDD-TA-T-004 v2015.10
10.4.3
Study Summary
An investigator's summary will be provided to Allergan within a short time after the 
completion of the study, or as designated by Allergan. A summary is also to be provided to 
the responsible IRB/IEC.
10.4.4
Retention of Documentation
All study related correspondence, patient records, consent forms, patient privacy 
documentation, records of the distribution and use of all IPs, and copies of case report forms 
should be maintained on file.
For countries falling within the scope of the ICH guidelines, Allergan-specific essential 
documents should be retained until at least 2 years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or at least 2 years have elapsed since the formal 
discontinuation of clinical development of the IP. These documents should be retained for a 
longer period, however, if required by the applicable regulatory requirement(s) or if needed 
by the sponsor.
In addition, for countries not falling within the scope of the ICH guidelines, local regulatory 
requirements should be followed regarding the retention of clinical study documentation.
Allergan requires that it be notified in writing if the investigator wishes to relinquish 
ownership of the data so that mutually agreed-upon arrangements can be made for transfer of 
ownership to a suitably qualified, responsible person.
10.5
Labeling, Packaging, and Return or Disposal of Investigational 
Products/Treatments
10.5.1
Labeling/Packaging
Ubrogepant will be supplied in blister cards and will be labeled with the protocol number, 
storage information, warning language, and instructions to take the tablets as directed. The 
card will also include the medication number. Immediately before dispensing the blister card, 
the principal investigator or designee will write the study center number, patient’s initials and 
identification number, and date on the card.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
56
GDD-TA-T-004 v2015.10
10.5.2
Clinical Supply Inventory
The investigator must keep an accurate accounting of the number of investigational units 
received from Allergan, dispensed or administered to the patients, the number of units 
returned to the investigator by the patient (if applicable), and the number of units returned to 
Allergan during and at the completion of the study. A detailed inventory must be completed 
for all used and unused ubrogepant and packaging. Ubrogepant must be dispensed or 
administered only by an appropriately qualified person to patients in the study. The 
medication is to be used in accordance with the protocol. 
10.5.3
Return or Disposal of Investigational Products/Treatments 
and/or Supplies
All ubrogepant packaging, either empty or containing unused ubrogepant, must be returned 
to the site. All clinical IPs/treatments and/or supplies will be returned to Allergan or Allergan 
designee for destruction.
10.6
Monitoring by Allergan
A representative of Allergan will monitor the study on a periodic basis. The determination of 
the extent and nature of monitoring will be based on considerations such as the objective, 
purpose, design, complexity, blinding, size, and endpoints of the study.
Authorized representatives of Allergan or regulatory authority representatives will conduct 
on-site visits to review, audit and copy study-related documents. These representatives will 
meet with the investigator(s) and appropriate staff at mutually convenient times to discuss 
study-related data and questions.
10.7
Handling of Biological Specimens/Samples
All urine pregnancy testing will be performed on site. Refer to your local laboratory manual 
for handling procedures.
Samples of blood and urine for evaluation of hematology, blood chemistry, and urinalysis 
will be analyzed at a centralized clinical laboratory with certification from a recognized 
accreditation agency (eg, College of American Pathology or Clinical Laboratory 
Improvement Amendments certification).

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
57
GDD-TA-T-004 v2015.10
10.8
Publications
Allergan, as the sponsor, has proprietary interest in this study. Authorship and manuscript 
composition will reflect joint cooperation between multiple investigators and sites and 
Allergan personnel. Authorship will be established prior to the writing of the manuscript. As 
this study involves multiple centers, no individual publications will be allowed prior to 
completion of the final report of the multicenter study except as agreed with Allergan.
10.9
Coordinating Investigator
A signatory coordinating investigator will be designated prior to the writing of the clinical 
study report.
11.
References
Cady RK, McAllister PJ, Spierings ELH, Messina J, Carothers J, Djupesland PG, et al. A 
randomized, double-blind, placebo-controlled study of breath powered nasal delivery of 
sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study). 
Headache 2015;55:88–100.
Connor KM, Shapiro RE, Diener HC, Lucas S, Kost J, Fan X, et al. Randomized, 
controlled trial of telcagepant for the acute treatment of migraine. Neurology. 
2009 Sep 22;73(12):970-977.
Food and Drug Administration Guidance for Industry. Drug-Induced Liver Injury: 
Premarketing Clinical Evaluation (UCM174090) July, 2009. 
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf
Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies 
characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann 
Neurol. 1993;33(1):48–56.
Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. 
Implications of recent clinical trials for the National Cholesterol Education Program Adult 
Treatment Panel III Guidelines. J Am Coll of Cardiology. 2004;44:720–732.
Hartmaier SL, Santanello NC, Epstein RS, Silberstein SD. Development of a brief 24-hour 
migraine - specific quality of life questionnaire. Headache. 1995;35:320–329.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
58
GDD-TA-T-004 v2015.10
Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United 
States. Arch Intern Med. 1999;159:813–818.
Headache Classification Committee of the International Headache Society (IHS). 
The International Classification of Headache Disorders, 3rd edition (beta version). 
Cephalalgia. 2013;33(9):629–808. http://www.ihs-
classification.org/_downloads/mixed/InternationalHeadache-Classification-III-ICHD-III-
2013-Beta.pdf.
Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic 
migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86–92.
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed MI, Stewart WF, on behalf of the AMPP 
advisory group. Migraine prevalence, disease burden, and the need for preventive therapy. 
Neurol. 2007;68(5):343–349.
National Cholesterol Education Program Adult Treatment Panel III Guidelines. NIH 
Publication No. 01-3670, May 2001. http://www.scymed.com/en/smnxdj/edzr/edzr9610.htm. 
Olesen J, Diener H-C, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin 
gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. 
N Engl J Med. 2004;350(11):1104–1110.
Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, et al. Headache 
Classification Committee. New appendix criteria open for a broader concept of chronic 
migraine. Cephalalgia. 2006;26(6):742–746.
Santanello NC, Hartmaier SL, Epstein RS, Silberstein SD. Validation of a new quality of life 
questionnaire for acute migraine headache. Headache.1995;35:330–337.
Stovner LJ, Andree C. Prevalence of headache in Europe:  a review for the Eurolight Project. 
J Headache Pain. 2010;11:289–299.
Tepper SJ, Cady RK, Silberstein S, Messina J, Mahmoud RA, Djupesland PG, et al. AVP 
825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 
100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a 
comparative randomized clinical trial across multiple attacks. Headache. 
2015;55(5):621-635.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
59
GDD-TA-T-004 v2015.10
12.
Attachments
12.1
Examination Procedures, Tests, Equipment, and Techniques
12.1.1
International Classification of Headache Disorders, 3rd Edition, 
Beta Version

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
60
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
61
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
62
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
63
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
64
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
65
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
66
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
67
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
68
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
69
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
70
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
71
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
72
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
73
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
74
GDD-TA-T-004 v2015.10

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
75
GDD-TA-T-004 v2015.10
12.2
Examples of Prohibited Medications
Prohibited Medications
The following medications are prohibited 30 days prior to Screening and throughout the 
study period for patients taking ubrogepant. Note that for patients assigned to the usual-care
arm, these restrictions do not apply.
Strong/Moderate CYP3A4 Inducers
Strong/Moderate CYP3A4 Inhibitors
Antidepressant/ 
Antianxiety
Barbiturates 
•
Amobarbital (Amytal®)
•
Aprobarbital (Alurate®)
•
Butalbital (Fiorinal®, 
Fioricet®)
•
Butabarbital (Busodium®, 
Butisol®)
•
Mephobarbital (Mebaral®)
•
Pentobarbital (Nembutal®)
•
Phenobarbital (Luminal®, 
Solfoton®)
•
Secobarbital (Seconal®)
Nefazodone (Serzone®)
Antiseizure
Carbamazepine (Atretol®, Carbatrol®, 
Epitol®, Equetro®, Tegretol®)
Oxcarbazepine (Trileptal®) 
Phenytoin (Dilantin®, Phenytek®)
Primidone (Myidone®, Mysoline®)
Diabetes
Pioglitazone (Actos®)
Troglitazone (Rezulin®, Resulin®)
Antiemetic
Aprepitant (Emend®)
Antihypertension
Diltiazem (Cardizem®)
Verapamil (Calan®, Calan SR®)
Glucocorticoid 
(Systemic)
Betamethasone (Celestone®)
Dexamethasone (Baycadron®, 
DexPak®)
Hydrocortisone (Cortef®)
Methylprednisolone (Medrol®)
Prednisolone (Prelone®)
Prednisone (Deltasone®)
Triamcinolone (Kenalog®)
Antibiotics
Rifabutin (Mycobutin®) 
Rifampicin/Rifampin (Rifadin®, 
Rifater®, Rimactane®) 
Erythromycin ( Benzamycin®,
EryTab®)
Clarithromycin (Biaxin®)
Telithromycin (Ketek®)
Antifungal
Fluconazole (Diflucan®, Trican®)
Itraconazole (Sporanox®)
Ketoconazole (Nizoral®)

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
76
GDD-TA-T-004 v2015.10
Strong/Moderate CYP3A4 Inducers
Strong/Moderate CYP3A4 Inhibitors
Anti-HIV
Efavirenz (Stocrin®, Sustiva®) 
Nevirapine (Viramune®)
Indinavir (Crixivan®)
Nelfinavir (Viracept®) 
Ritonavir (Norvir®)
Saquinavir (Fortovase®, Invirase®)
Immunosuppressant
Cyclosporine - oral/intravenous only 
(Neoral®, Sandimmune®)
Other
St John’s wort
Enzalutamide (Xtandi®)
Modafinil (Provigil®)
Buprenorphine (Cizol®, Subutex®, 
Suboxone®)
Quinine, armodafinil (Nuvigil TM)
Drugs with Narrow Therapeutic Margins
Warfarin (Coumadin®)
Digoxin (Digitek®, Lanoxin®, Digox®)
Cisapride (Prepulsid®, Propulsid®) 
Pimozide (Orap®)
The following medications are allowed during the study; however, they are prohibited within 
48 hours prior to taking ubrogepant:
Triptan
Almotriptan (Axert®)
Eletriptan (Relpax®)
Frovatriptan (Frova®)
Naratriptan (Amerge®)
Rizatriptan (Maxalt®) 
Sumatriptan (Imitrex®) 
Zolmitriptan (Zomig®)
Ergot Derivative
Dihydroergotamine (DHE 45®, Migranal®)
Ergotamine (Cafergot®, Ergomar®, Wigraine®)
Opioid
Tramadol (eg, Ultracet®, Ultram®)
Butorphanol (Stadol®)
Codeine-containing analgesics (eg, Tylenol with Codeine #3®)
Hydrocodone (Zohydro ER™)/Hydrocodone-containing analgesics 
(eg, Vicodin®)
Oxycodone (Oxycontin®, Roxicodone®)/Oxycodone-
containing analgesics (eg, Percocet®) 
Morphine (MS Contin®)
NSAID
Aspirin 
Combination medicines with NSAIDS (eg, Excedrin®)
Diclofenac (Arthrotec®, Cataflam®, Voltaren®)
Ibuprofen (eg, Advil®, Excedrin IB®, Motrin®)
Ketoprofen (eg, Orudis®) 
Naproxen (eg, Aleve®, Naprosyn®)
Analgesic
Acetaminophen (eg, Tylenol® or any combination drug Tylenol®)

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
77
GDD-TA-T-004 v2015.10
Antiemetic agent
Chlorpromazine (Thorazine®)
Hydroxyzine (Vistaril®)
Metoclopramide (Reglan®)
Ondansetron (Zofran®)
Prochlorperazine (Compazine®)
Promethazine (Phenergan®, Mepergan®)
Proton Pump Inhibitor
Esomeprazole (Nexium®)
Lansoprazole (Prevacid®, Zoton®)
Omeprazole (Losec®, Prilosec®, Zegerid®)
Pantoprazole (Pantoloc®, Pantozol®, Protonix®, Somac®, Zurcal®) 
Rabeprazole (Aciphex®, Pariet®, Rabecid®)
The following medications are allowed during the study; however, they are prohibited within 
24 hours prior to taking ubrogepant:
Antacid
Aluminum Carbonate Gel (Basaljel®)
Aluminum Hydroxide (AlternaGEL®, Amphojel®)
Aluminum Hydroxide and magnesium hydroxide (Maalox®, Mylanta®)
Bismuth Subsalicylate (Pepto-bismol®)
Calcium Carbonate (Alcalak®, Quick-Eze®, Rennie®, Rolaids®, Titralac®, 
TUMS®)
Hydrotalcite (Talcid®)
Magaldrate plus Simethicone (Pepsil®)
Magnesium Hydroxide (Phillips' Milk of Magnesia®)
Sodium Bicarbonate (Alka-Seltzer®, Bicarbonate of Soda®)
H2 Blocker
Famotidine (Pepcid®)
Nizatidine (Axid®)
Ranitidine (Zantac®)
Cimetidine (Tagamet®)

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
78
GDD-TA-T-004 v2015.10
12.3
Glossary of Abbreviations
Term/Abbreviation
Definition
AE
adverse event
ALCOA
attributable, legible, contemporaneous, original, and accurate
ALP
alkaline phosphatase
ALT
alanine aminotransferase
AST
aspartate aminotransferase
BCRP
breast cancer resistance protein
CGRP
calcitonin gene-related peptide
CGRP RA
CGRP receptor antagonist
CHD
coronary heart disease
CRO
contract research organization
C-SSRS
Columbia-Suicide Severity Rating Scale
CV
cardiovascular
CYP
cytochrome P450
CYP3A4
cytochrome P450 3A4
ECG
electrocardiogram
eCRF
electronic case report form
eDISH
evaluation of drug-induced serious hepatotoxicity
ET
early termination
GCP
Good Clinical Practices
HEOR
Health Economics and Outcomes Research
HIPAA
Health Insurance Portability and Accountability Act
HIV
human immunodeficiency virus
ICF
informed consent form
ICH
International Conference on Harmonization
ICHD-3 beta
International Classification of Headache Disorders criteria, 3rd 
edition beta version
IEC
Independent Ethics Committee
INR
international normalized ratio (blood-clotting test)
IP
investigational product

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
79
GDD-TA-T-004 v2015.10
IRB
Institutional Review Board
IV
intravenous
IWRS
interactive web response system
LOCF
last observation carried forward
mITT
modified intent-to-treat
NCEP
National Cholesterol Education Program
NSAID
nonsteroidal anti-inflammatory drug
PCS
potentially clinically significant
PCR
polymerase chain reaction
PF
pain freedom
PR
pain relief
PR interval
the period from the beginning of the P wave (the onset of atrial 
depolarization) until the beginning of the QRS complex (the onset of 
ventricular depolarization)
QoL
Quality-of-Life
QRS interval
part of ECG corresponding to the depolarization of the right and left 
ventricles of the human heart.
QT interval
time between the start of the Q wave and the end of the T wave in the 
heart's electrical cycle. The QT interval represents electrical 
depolarization and repolarization of the ventricles.
QTc
QT interval corrected for heart rate
QTcF
QT interval corrected for heart rate using the Fridericia formula 
(QTcF = QT/(RR)⅓)
RR interval
interval between R waves in ECG
SAE
serious adverse event
SAP
statistical analysis plan
SD
standard deviation
SNRI
serotonin norepinephrine reuptake inhibitors
SPF
sustained pain freedom
SSRI
selective serotonin reuptake inhibitors
TBL
total bilirubin
TEAE
treatment-emergent adverse event
ULN
upper limit of normal

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
80
GDD-TA-T-004 v2015.10
US
United States
WOCBP
women of childbearing potential

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
81
GDD-TA-T-004 v2015.10
12.4
Protocol Amendment 1 Summary
Title:  A Multicenter, Randomized, Open-label Extension Study to Evaluate the Long-term 
Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or 
Without Aura
Protocol UBR-MD-04 Amendment 1
Date of Amendment:  15 Nov 2016
Amendment Summary
This summary includes changes made to Protocol UBR-MD-04 (02 May 2016). This 
protocol was amended to:  1) update health outcomes measures and efficacy variables; and 
2) clarify Exclusion Criterion 2. Following is a summary of content-oriented changes that 
were made to each section of the protocol, and a brief rationale for these changes. Minor 
editorial and document formatting revisions have not been summarized.
Section
Revision
Rationale
Global Change
In reference to the Satisfaction With Study 
Medication assessment, instances of 
“migraine treatment” were changed to “study 
medication”
Based on input from patient 
qualitative interviews, expert 
panel suggested rephrasing 
“migraine treatment” to “study 
medication”
Global Change
Revised SAE/Pregnancy Reporting Fax 
Number
Administrative update
Global Change
 
 
Global Change
 
 
 
 
Protocol Title Page
Revised name of the Authorized US Agent 
from Allergan, Inc. to Allergan Sales, LLC
Administrative update
 
Administrative update

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
82
GDD-TA-T-004 v2015.10
Section
Revision
Rationale
Protocol Summary –
General Statistical 
Methods and Types of 
Analyses
 
 
 
 
 
 
 
 
 
 
 
 
, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 3.1, Section 
Title
Section title and in-text change updated to 
“Data Drug Safety Monitoring Board” 
Clarification

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
83
GDD-TA-T-004 v2015.10
Section
Revision
Rationale
Section 4.4,
 
 
 
 
 
 
 
 
 
 
Clarification
Section 4.5.1, 
Permissible 
Medications/Treatments
Added text regarding prohibited and allowed 
medications for those assigned to the 
usual-care arm:
Medications that are not specifically 
prohibited are allowed, with the following 
clarifications and restrictions for patients 
taking ubrogepant. Note that for patients 
assigned to the usual-care arm, these 
restrictions do not apply.
Clarification to note that 
restrictions on medications do 
not apply to patients in the 
usual-care arm
Deleted “any proton pump inhibitor” from
list of medications  prohibited within 24
hours prior to taking IP and added it to list of 
medications prohibited within 48 hours prior 
to IP dosing
Amended per FDA request
Section 4.5.1.2,
Definition of Females of 
Childbearing Potential 
and/or Acceptable 
Contraceptive Methods
Moved surgical sterilization from a method 
of contraception to defining WOCBP:
For the purposes of this study, females will 
be considered of childbearing potential 
unless they are naturally postmenopausal (ie, 
no menses for 2 years) or permanently 
sterilized (ie, bilateral tubal ligation, bilateral 
salpingectomy, bilateral oophorectomy or
hysterectomy).
Clarification

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
84
GDD-TA-T-004 v2015.10
Section
Revision
Rationale
Section 4.5.1.2,
Definition of Females of 
Childbearing Potential 
and/or Acceptable 
Contraceptive Methods
Updated acceptable contraceptive methods:
For WOCBP who may participate in the 
study, the following methods of 
contraception, if properly used, are generally 
considered reliable: hormonal contraceptives 
(ie, oral, patch, vaginal ring, injection, 
implant), male condom with intravaginal 
spermicide, diaphragm or cervical cap with 
spermicide, vaginal contraceptive ring, 
intrauterine device, surgical sterilization 
(bilateral tubal ligation, bilateral 
salpingectomy), vasectomized partner, or 
sexual abstinence….. Male participants must 
also refrain from donating sperm during the 
course of the study.
Clarification
Section 4.5.2,
Prohibited 
Medications/Treatments
Added text regarding prohibited medication: 
The following medications are prohibited 
throughout the study period for patients 
taking ubrogepant. Note that for patients 
assigned to the usual-care arm, these 
restrictions do not apply.
Clarification to note that 
restrictions on medications do 
not apply to patients in the 
usual-care arm
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
85
GDD-TA-T-004 v2015.10
Section
Revision
Rationale
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 6.3,
Other Study Supplies
Deleted Allergan-supplied thermometer from 
list of Allergan-provided supplies:

ElPro Libero thermometer
Clarification to note that 
Allergan will not provide a 
thermometer
 
 
 
 
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
86
GDD-TA-T-004 v2015.10
Section
Revision
Rationale
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 8.8,
Early Discontinuation of 
Patients
Revised text regarding prematurely 
discontinued patients: 
A final assessment will be defined as 
completion of the evaluations scheduled for 
Visit 15/ET. If the patient discontinues 
prematurely after ubrogepant is taken,, the 
patient is expected to return for a safety 
follow-up visit 4 weeks postdose after 
Visit 15/ET.
Clarification to note that all 
patients, independent of 
randomization treatment arm, 
will need to return for a Safety 
Follow-up visit
Section 9.5,
ALT or AST Elevations
Revised re-challenge text: If a patient is not 
rechallenged with IP, the patient must  be 
discontinued from the study and complete the 
Early Termination Visit 15 and Safety 
Follow-Up Visit 16. Patients should receive 
appropriate follow-up as per standard of care.
Clarification regarding follow-up 
if the patient is not rechallenged 
with IP
Section 11, References
Added Cady and Tepper references
Administrative update

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
87
GDD-TA-T-004 v2015.10
Section
Revision
Rationale
Section 12.2,
Examples of Prohibited 
Medications
Revised introductory text: 
The following medications are prohibited 
30 days prior to Screening and throughout 
the study period for patients taking 
ubrogepant. Note that for patients assigned to 
the usual-care arm, these restrictions do not 
apply.
Clarification to note that 
restrictions on medications do 
not apply to patients in the 
usual-care arm.
Deleted the following Proton Pump 
Inhibitors from the list of medications 
prohibited within 24 hours prior to IP dosing
and added them to the list of medications 
prohibited within 48 hours prior to IP dosing:
Esomeprazole (Nexium®)
Lansoprazole (Prevacid®, Zoton®)
Omeprazole (Losec®, Prilosec®, Zegerid®)
Pantoprazole (Pantoloc®, Pantozol®, 
Protonix®, Somac®, Zurcal®)
Rabeprazole (Aciphex®, Pariet®, Rabecid®)
Amended per FDA request
Added to “Others” category: armodafinil 
(NuvigilTM)
Clarification
Section 12.3,
Glossary of 
Abbreviations
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
88
GDD-TA-T-004 v2015.10
12.5
Protocol Amendment 2 Summary
Title:  A Multicenter, Randomized, Open-label Extension Study to Evaluate the Long-term 
Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or 
Without Aura
Protocol UBR-MD-04 Amendment 2
Date of Amendment:  06 Dec 2017
Amendment Summary
This summary includes changes made to Protocol UBR-MD-04 (02 May 2016) and Protocol 
Amendment 1 (15 Nov 2016). This protocol was amended to: 1) add a new health outcomes 
measure and update variables; 2) update the definition of the safety population. Following is 
a summary of content-oriented changes that were made to each section of the protocol, and a 
brief rationale for these changes. Minor editorial and document formatting revisions have not 
been summarized.
Section
Revision
Rationale
 
 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 
Clarification

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
89
GDD-TA-T-004 v2015.10
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section 7.1.2 Safety 
Population 
Definition changed as follows:
The Safety population will will be defined 
separately for the ubrogepant arms and the 
usual-care arm. 
Ubrogepant arms: All randomized patients who 
received ≥ 1 dose of treatment 
Usual care arm: All randomized patients in the 
usual-care arm. 
The purpose of the usual care arm is to
Definition of Safety population 
modified to include all 
randomized patients in the 
usual-care arm to better 
contextualize the safety 
findings for both arms.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
90
GDD-TA-T-004 v2015.10
contextualize any safety findings that may occur 
in the ubrogepant treated patients over the 
course of 12 months.  As such, data from all 
patients randomized to the usual care arm, 
regardless of whether the patient used 
medication to treat migraine, will be included in 
the safety analyses.
 
 
 
 
 
 
 
 
 
 
Section 7.3.2.1 Adverse 
Events
Defined first dose of treatment in the lead-in 
study throughout section
Clarification
AE redefined:
An AE that occurs after Visit 16 for patients 
with Visit 16 or more than 30 days after the last 
dose of treatment visit for patients without Visit 
16 will not be considered as a TEAE.
Clarification
The number and percentage of patients 
reporting TEAEs after randomization in each 
treatment group will be tabulated by descending 
percentage in any group, by system organ class 
and preferred term, and further categorized by 
severity and causal relationship to the study 
treatment. 
Clarification
An SAE that occurred between the date of the 
first dose of treatment in the lead-in study and 
Visit 16 for patients with Visit 16 or within 30 
days after the last dose of treatment visit for 
patients without Visit 16, inclusive, will be 
considered an on-therapy SAE. The number and 
percentage of patients who have on-therapy 
SAEs after the first dose of treatment
randomization will be summarized by preferred 
term and treatment group. In addition, the 
incidence of on-therapy SAEs that led to death 
will be summarized separately by preferred 
term for each treatment group. 
Clarification
Section 7.3.2.3 Clinical 
Laboratory Parameters
Text clarified as follows:
Any post-treatment ALT and/or AST results 
that are ≥ 3 times the ULN are considered 
events of clinical interest in this study and are 
patient subject to blinded adjudication by the 
Clinical Adjudication Committee to determine 
whether the elevation is due to treatment or not, 
Typo

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
91
GDD-TA-T-004 v2015.10
and to determine whether there is a confounding 
factor. 
Section 7.3.2.4 Vital Signs 
Measurements
Added BMI:
Descriptive statistics for vital sign 
measurements (sitting and standing systolic and 
diastolic BP, sitting and standing pulse rate, 
respiratory rate, temperature, and weight, and 
BMI) and changes from baseline values at each 
visit and at the end of study will be presented by 
treatment group. 
Administrative change
7.3.2.6
Suicidality 
Assessment
Timing of assessment amended as follows:
For the C-SSRS, the number of patients with 
suicidal ideation and suicidal behavior in 
lifetime history, during the treatment period, 
and during the safety follow-up period after the 
first dose of treatment will be summarized by 
treatment group for the Safety population. 
Clarification
Section 7.3.2.7 Potential 
Hy’s Law
Timing of assessment amended as follows:
Patients who meet the potential Hy’s Law 
criteria from the first dose of treatment
randomization to Visit 16 will be summarized. 
Supportive tabular displays also will be 
provided. 
Clarification
 
 
 
 
 
 
 
 
 
Section 9.3 Procedures for 
Reporting a Serious 
Adverse Event
Notify Allergan immediately by fax or email 
using the serious adverse eventSAE form 
(contact details can be found on page 1 of the 
serious adverse event SAE form); the fax 
number is on the front page of this protocol, and
phone numbers and relevant Allergan personnel 
contacts are also on the frontstudy contacts page 
of protocol.
Changed to show correct 
location of study contact 
details

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
92
GDD-TA-T-004 v2015.10
Section 9.5 ALT or AST
Elevations
For this repeat testing, the following tests 
should be performed: hematology and 
chemistry panels, international normalized ratio 
(INR), and a urine toxicology screen for 
acetaminophen. 
The toxicology screen for 
acetaminophen will not be 
tested from urine samples
Section 11 References
 
 
 
Santanello NC, Hartmaier SL, Epstein RS, 
Silberstein SD. Validation of a new quality of 
life questionnaire for acute migraine headache. 
Headache 1995;35:330-337.
O’Brien P. Procedures for comparing samples 
with multiple endpoints. Biometrics 
1984;40:1079-1087.
Reference added to support 
Section 7.3.1 Efficacy 
Analyses
 
12.6
Protocol Amendment 3 Summary
Title:  A Multicenter, Randomized, Open-label Extension Study to Evaluate the Long-term 
Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or 
Without Aura
Protocol UBR-MD-04 Amendment 3
Date of Amendment: 11 Apr 2018
Amendment Summary
This summary includes changes made to Protocol UBR-MD-04 (02 May 2016), Protocol 
Amendment 1 (15 Nov 2016), and Protocol Amendment 2 (06 Dec 2017). This protocol 
was amended primarily to add information regarding an interim analysis, update efficacy 
endpoints, and add a subgroup analysis for safety. Following is a summary of 
content-oriented changes that were made to each relevant section of the protocol and a brief 
rationale for each of these changes. If needed to clarify revisions, added text is shown in bold 
italics and deleted text is shown with strikethroughs. Minor editorial and document 
formatting revisions have not been summarized.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
93
GDD-TA-T-004 v2015.10
Section
Revision
Rationale
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Summary –
Study Design
The following revision was made in the 
“Structure” section of the protocol summary:
Structure: multicenter, randomized, open-
label, 52-week extension study; 
randomization to the ubrogepant arms (50 
and 100 mg) will be blinded
This information was 
removed to avoid 
redundancy.
Protocol Summary –
General Statistical 
Methods and Types of 
Analyses
Changes made to this section are described 
below.
 
 
 
 
 
 
3.
The safety analyses information was 
revised as follows:
The safety analyses will be performed using 
the Safety population and will include AEs, 
clinical laboratory evaluations, vital sign 
measurements, ECG parameters, and the 
C-SSRS. For each of the clinical, laboratory, 
vital sign, and ECG parameters, the last 
nonmissing safety assessment before the first 
dose of treatment the first dose in the lead-in 
study will be used as the baseline for all 
analyses of that safety parameter. Continuous 
variables will be summarized by the number 
of patients and mean, SD, median, minimum, 
and maximum values. Categorical variables 
 
 
 
 
 
The safety analyses 
information was changed as 
a clarification.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
94
GDD-TA-T-004 v2015.10
will be summarized by number and 
percentage of patients.
Protocol Summary –
General Statistical 
Methods and Types of 
Analyses
The following statement was removed from 
this section: “Summary statistics for the 
patient-specific monthly attack rates will be 
provided by treatment groups.”
This information was 
removed because this 
analysis is no longer being 
performed for efficacy but 
will be summarized for the 
Safety Population.
Protocol Summary –
General Statistical 
Methods and Types of 
Analyses
 
 
 
 
 
 
 
 
 
Section 3 – Study 
Design
The following revision was made in this 
section:
This multicenter, randomized, open-label, 
52-week extension study will enroll 
approximately 1200 patients from 
approximately 200 centers in the United 
States. Patients will be randomized (1:1:1) to 
1 of the following 3 treatment groups: usual 
care, ubrogepant 50 mg, or ubrogepant 
100 mg (400 patients per arm). The study is 
open-label; however, randomization to the 
ubrogepant arms (50 and 100 mg) will be 
blinded. If and when an interim analysis 
occurs, the doses will be unblinded (see 
Section 7.6).
The randomization to the 
ubrogepant arms has been 
blinded; however, this 
section was revised because 
after the interim analysis, if 
performed, Allergan will be 
unblinded to the ubrogepant 
doses. Sites and patients 
will remain blinded 
throughout the study. 
Details of the interim 
analysis and blinding are 
provided in Section 7.6.
Section 5.4 –Treatment 
Allocation Ratio and 
Stratification
The following revision was made in this 
section:
Patients will be randomized (1:1:1) to 1 of 
the following 3 treatment groups: usual-care, 
ubrogepant 50 mg, or ubrogepant 100 mg. 
The study is open-label; however, 
randomization to the ubrogepant arms 
(50 and 100 mg) will be blinded. If and 
when an interim analysis occurs, the doses 
will be unblinded (see Section 7.6).
The randomization to the 
ubrogepant arms has been 
blinded; however, this 
section was revised because 
after the interim analysis, if 
performed, Allergan will be 
unblinded to the ubrogepant 
doses. Sites and patients 
will remain blinded 
throughout the study. 
Details of the interim 
analysis and blinding are 
provided in Section 7.6.
 
 
 
 
 
 
 
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
95
GDD-TA-T-004 v2015.10
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
96
GDD-TA-T-004 v2015.10
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
97
GDD-TA-T-004 v2015.10
 
 
 
 
 
 
 
.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
98
GDD-TA-T-004 v2015.10
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3.2 – Safety Analyses
The safety analyses information was revised 
as follows:
The safety analyses will be performed using 
the Safety population. The safety parameters 
will include AEs, clinical laboratory 
evaluations, vital sign measurements, ECG 
parameters, and the C-SSRS. For each of the 
clinical, laboratory, vital sign, and ECG 
parameters, the last nonmissing safety 
assessment before the first dose of treatment
in the lead-in study will be used as the 
baseline for all analyses of that safety 
parameter. 
The safety analyses 
information was revised as a 
clarification.
7.3.2.1 – Adverse Events
The following revision was made regarding 
the definition of a TEAE:
An AE that occurs after Visit 16 for patients 
with Visit 16, or more than 30 days after the 
last visit or last treatment, whichever is 
later, for patients without Visit 16 will not be 
This information was 
revised as a clarification.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
99
GDD-TA-T-004 v2015.10
considered as a TEAE.
7.3.2.1 – Adverse Events
The statement regarding tabulation of 
TEAEs was revised as follows:
The number and percentage of patients 
reporting TEAEs after randomization in each 
treatment group will be tabulated by 
descending percentage in any the highest 
dose group, by system organ class and 
preferred term, and further categorized by 
severity and causal relationship to the study 
treatment. 
This information was 
revised as a clarification.
7.3.2.1 – Adverse Events
The following revisions were made 
regarding the definition of an SAE and the 
summarization of deaths:
A SAE that occurred between the date of the 
first dose of treatment in the lead-in study 
and Visit 16 for patients with Visit 16, or 
within 30 days after the last visit or last 
treatment, whichever is later, for patients 
without Visit 16, inclusive, will be 
considered an on-therapy SAE. The number 
and percentage of patients who have 
on-therapy SAEs after randomization will be 
summarized by preferred term and treatment 
group. In addition, the incidence of on-
therapy SAEs that led to death will be
summarized separately by preferred term for 
each treatment group.
The definition of SAE was 
revised as a clarification.
The statement regarding 
summarization of death was 
removed because this 
information will not be 
presented in tabular format.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
100
GDD-TA-T-004 v2015.10
7.3.2.1 – Adverse Events
The following revisions were made 
regarding summarization of TEAEs of 
special interest:
The number and percentage of patients 
with TEAEs of clinical interest will be 
summarized by preferred term and 
treatment group. TEAEs of clinical 
interest include triptan-associated TEAEs, 
abuse-related TEAEs, hepatic injury 
TEAEs, cardiac arrhythmias TEAEs, 
central nervous system TEAEs, vascular 
disorders TEAEs, embolic and thrombotic 
events TEAEs, hypertension TEAEs, 
ischemic heart disease TEAEs, and 
suicide/self-injury TEAEs. The number and 
percentage of patients who had triptan-
associated AEs also will be summarized by 
treatment group. The triptan-associated AE 
class consists of the following individual 
AEs: any chest pain, chest tightness, throat 
tightness, asthenia, paresthesia, dysesthesia, 
and hyperesthesia.
The paragraph regarding 
summarizations of TEAEs 
of special interest was 
revised because of a change 
in the way this information 
is being presented.
Section 7.4 – Subgroup 
Analyses
The following revision was made to this 
section:
Subgroup analyses will be done for 
disposition, treatment exposure, and TEAEs 
for sex, age group (< 40 vs ≥40, and < 65 vs 
≥65), race (white vs all other races), 
cardiovascular risk category, and renal 
function class.No subgroup analysis is 
planned for this study.
This information was added 
because subgroup analyses 
are now planned for this 
study.
 
 
 
 
 
 
 
 
 
 
 
Section 7.6 – Interim 
Analysis
This section has been revised to include 
information regarding an interim analysis, as 
follows:
No interim analysis is planned for this study.
The interim analysis for Study UBR-MD-04 
will occur when at least 300 ubrogepant 
patients (with a minimum of 2 migraines 
treated with ubrogepant per month, on 
average) have been enrolled in 
Study UBR-MD-04 for 6 months and 
200 ubrogepant patients (with a minimum 
This new information was 
added because an interim 
analysis is now planned for 
this study if requirements 
are met.

Allergan Confidential
Protocol UBR-MD-04 Amendment 3
101
GDD-TA-T-004 v2015.10
of 2 migraines treated with ubrogepant per 
month, on average) have been enrolled in 
Study UBR-MD-04 for 1 year. 
In regards to blinding, although this is an 
open-label study, randomization to the 
ubrogepant 50 mg or 100 mg arms is 
blinded. If and when an interim analysis 
occurs, Allergan staff will be unblinded to 
the ubrogepant doses; however, patients 
and sites will remain blinded. The interim 
analysis will include all analyses specified 
in the SAP except for efficacy analyses.
Details regarding the interim analysis are
specified in the SAP.